Drug Disposition in the Mammalian Eye and Brain: A Comparison of Mechanisms

References

• Oppenheimer S. B. Introduction to Embryonic Development. Allyn and Bacon, Boston 1980
   Google Scholar
• Shepherd G. M. Synaptic Organisation of the Brain. Oxford University Press, London 1974
   Google Scholar
• Betz A. L. Transport of ions across the blood-brain barrier. Fed. Proc 1986; 45: 2050–2054
   PubMedGoogle Scholar
• Pardridge W. M., Choi T. B. Neutral amino acid transport at the human blood-brain barrier. Fed. Proc 1984; 45: 2073–2078
   Google Scholar
• Pautler E. L., Tengerdy C. Transport of acidic amino acids by the bovine pigment epithelium. Exp. Eye Res. 1986; 43: 207–214
   PubMed Web of Science ®Google Scholar
• Goodchild M., Neal M. J. The uptake of 3H-7-aminobutyric acid by the retina. Brit. J. Pharmacol. 1973; 47: 529–542
   PubMed Web of Science ®Google Scholar
• Steele R. D. Blood-brain barrier transport of the a-keto acid analogs of amino acids. Fed. Proc 1986; 45: 2060–2064
   PubMedGoogle Scholar
• Spector R., Eells J. Deoxynucleoside and vitamin transport into the central nervous system. Fed. Proc 1984; 43: 196–200
   PubMedGoogle Scholar
• Heath H., Fiddick R. The active transport of ascorbic acid in the rat retina. Exp. Eye Res. 1966; 5: 156–163
   PubMed Web of Science ®Google Scholar
• Neal M. J., Gilroy J. High-affinity choline transport in the isolated retina. Brain Res. 1975; 93: 548–551
   PubMed Web of Science ®Google Scholar
• Cornford E. M., Braun L. D., Oldendorf W. H. Carrier mediated blood-brain barrier transport of choline and certain choline analogs. J. Neurochem. 1978; 30: 299–308
   PubMed Web of Science ®Google Scholar
• Banks W. A., Kastin A. J., Fischman A. J., Coy D. H., Strauss S. L. Carrier-mediated transport of enkephalins and /V-Tyr-MIF-1 across blood-brain barrier. Am. J. Physiol. 1986; 251: E477–E482
   PubMed Web of Science ®Google Scholar
• van Bree J. B. M. M., de Boer A. G., Verhoef J. C., Danhof M., Breimer D. D. Transport of vasopressin fragments across the blood-brain barrier: in vitro studies using monolayer cultures of bovine brain endothelial cells. J. Pharmacol. Exp. Ther. 1989; 249: 901–905
   PubMed Web of Science ®Google Scholar
• Bodor N. Novel approaches to the design of safer drugs: Soft drugs and site-specific chemical delivery systems. Adv. Drug Res. 1984; 13: 255–331
   Google Scholar
• Lee V. H. L. Topical ocular drug delivery: recent advances and future perspectives. Pharmacy International 1985; 6: 135–138
   Google Scholar
• Lee V. H. L., Urrea P. T., Smith R. E., Schanzlin D. J. Ocular drug bioavailability from topically applied liposomes. Survey Ophthalmol. 1985; 29: 335–348
   PubMed Web of Science ®Google Scholar
• Fraunfelder F. T., Meyer S. M. Drug-induced Ocular Side Effects and Drug Interactions. Lea and Febiger, Philadelphia 1988
   Google Scholar
• Kremers J. J. M., van Norren D. Retinal damage in macaque after white light exposure lasting ten minutes to twelve hours. Invest. Ophthalmol. Vis. Sci. 1989; 30: 1032–1040
   PubMed Web of Science ®Google Scholar
• Varma S. D., Kumar S., Richards R. D. Light-induced damage to ocular lens cation pump: Prevention by vitamin C. Proc. Natl. Acad. Sci. USA 1979; 76: 3504–3506
   PubMed Web of Science ®Google Scholar
• Varma S. D., Rice D., Deleon-Cuello A. M., Richards R. D. Mechanism of in vitro photodynamic damage to lens. Lens Research 1984–1985; 2: 145–157
   Google Scholar
• Kurnik R. T., Burde R. M., Becker B. Breakdown of the blood-aqueous barrier in the rabbit eye by infrared radiation. Invest. Opthalmol. Vis. Sci. 1989; 30: 717–722
   PubMed Web of Science ®Google Scholar
• Ohmori S., Nose H. Physical changes in bovine lens homoge-nate following ultraviolet irradiation and their prevention by some compounds. Chem. Pharm. Bull. 1985; 33: 2432–2437
   PubMed Web of Science ®Google Scholar
• Zigman S. Photobiology of the lens. Ocular Lens, Maisel. Dekker, New York 1985; 303–347
   Google Scholar
• Ehling U., Krokowski E. Schaden durch Rontgenstrahlen am Kaninchenauge in Abhangigkeit von Dosis und Strahlenqualitat. Fortschr. Rontgenstrahlen und Nuklearmed. 1957; 86: 469–477
   PubMedGoogle Scholar
• Matsuda H., Giblin F. J., Reddy V. N. The effect of X-irradiation on cation transport in rabbit lens. Exp. Eye Res. 1981; 33: 253–265
   PubMed Web of Science ®Google Scholar
• Matsuda H., Giblin F. J., Reddy V. N. The effect of X-irradiation on NaK ATPase and cation distribution in rabbit lens. Invest. Ophthalmol. Vis. Sci. 1982; 22: 180–185
   PubMed Web of Science ®Google Scholar
• Ehling U. H., Favor J., Kratochvilova J., Neuhauser-Klaus A. Dominant cataract mutations and specific-locus mutations in mice induced by radiation or ethylnitrosurea. Mutat. Res. 1982; 92: 181–192
   PubMed Web of Science ®Google Scholar
• Kratochvilova J., Favor J. Phenotypic characterization and genetic analysis of twenty dominant cataract mutations detected in offspring of irradiated male mice. Genet. Res., Camb. 1988; 52: 125–134
   PubMedGoogle Scholar
• Ehling U. H. Induction and manifestation of hereditary cataracts. Assessment of Risk from Low-Level Exposure to Radiation and Chemicals, A. D. Woodhead, C. J. Shellabarger, V. Pond, A. Hollaender. Plenum. 1985; 345–367
   Google Scholar
• Giblin F. J., McCready J. P., Schrimscher L., Reddy V. N. Peroxide-induced effects on lens cation transport following inhibition of glutathione reductase activity in vitro. Exp. Eye Res. 1987; 45: 77–91
   PubMed Web of Science ®Google Scholar
• West S., Munoz B., Emmett E. A., Taylor H. R. Cigarette smoking and risk of nuclear cataracts. Arch. Ophthalmol. 1989; 107: 1166–1169
   PubMed Web of Science ®Google Scholar
• Shearer T. R., David L. L., Anderson R. S. Selenite cataract: A review. Curr. Eye Res. 1987; 6: 289–300
   PubMed Web of Science ®Google Scholar
• Clark J. I., Danford M. E. Low Temperature and acrylamide inhibit lens opactification caused by calcium. Ophthalmic Res. 1985; 17: 246–250
   PubMed Web of Science ®Google Scholar
• Kinoshita J. H. Mechanisms initiating cataract formation. Invest. Ophthalmol. 1974; 13: 713–724
   PubMedGoogle Scholar
• Simoons F. J. A geographic approach to senile cataract–Possible links with milk consumption, lactase activity, and galactose metabolism. Digest. Dis. Sci. 1982; 27: 257–264
   PubMed Web of Science ®Google Scholar
• Cotlier E., Apple D. Cataracts induced by the polypeptide antibiotic polymyxin B sulfate. Exp. Eye Res. 1973; 16: 69–77
   PubMed Web of Science ®Google Scholar
• Iwata S., Horiuchi M. Studies on experimental cataracts induced by ionophores: In vitro effects of nigericin and valinomycin on the lenses in mice. Exp. Eye Res. 1980; 31: 543–551
   PubMed Web of Science ®Google Scholar
• Mizuno G. R., Chapman C. J., Chipault J. R., Pfeifer D. R. Lipid composition and (Na+ + K+)-ATPase activity in rat lens during triparanol-induced cataract formation. Biochim. Biophys. Acta 1981; 644: 1–12
   PubMed Web of Science ®Google Scholar
• Hightower K. R., Harrison S. E. Valinomycin cataracts: The relative role of calcium and sodium accumulation. Exp. Eye Res. 1982; 34: 941–943
   PubMed Web of Science ®Google Scholar
• Horiuchi M., Iwata S. Effect of nigericin on distribution of sodium, potassium and calcium ion in rabbit lens. Exp. Eye Res. 1983; 37: 439–445
   PubMed Web of Science ®Google Scholar
• Calvin H. I., Medvedovsky C., Worgul B. V. Near-total glutathione depletion and age-specific cataracts induced by buthionine sulfoximine in mice. Science 1986; 233: 553–555
   PubMed Web of Science ®Google Scholar
• Bluming A. Z., Zeegen P. Cataracts induced by intermittent use of Decadron used as an antiemetic. J. Clin. Oncol. 1986; 4: 221–223
   PubMed Web of Science ®Google Scholar
• Dieperink H., Steinbriichel D., Kemp E., Svendsen P., Star-klint H. Cataractogenic effect of cyclosporin A: A new adverse effect observed in the rat. Nephrol. Dial. Transplant. 1987; 1: 251–253
   PubMedGoogle Scholar
• Ellis E. F. Adverse effects of corticosteroid therapy. J. Allergy Clin. Immunol. 1987; 80: 515–517
   PubMed Web of Science ®Google Scholar
• Mandal K., Bose S. K., Chakrabarti B. Sensitizer-induced conformational changes in lens crystallin–I. Photodynamic action of methylene blue and W-formylkynurenine on bovine a-crystallin. Pho-tochem. Photobiol. 1986; 43: 515–523
   PubMed Web of Science ®Google Scholar
• Jernigan H. M., Jr. Role of hydrogen peroxide in riboflavin-sensitized photodynamic damage to cultured rat lenses. Exp. Eye Res. 1985; 41: 121–129
   PubMed Web of Science ®Google Scholar
• Rogers J. M., Grabowski C. T. Mirex-induced fetal cataracts: Lens growth, histology and cation balance, and relationship to edema. Teratology 1983; 27: 343–349
   PubMedGoogle Scholar
• Hope-Ross M., Travers S., Mooney D. Solar retinopathy following religious rituals. Brit. J. Ophthalmol. 1988; 72: 931–934
   PubMed Web of Science ®Google Scholar
• Bernstein H. N., Ginsberg J. The pathology of chloroquine retinopathy. Arch. Ophthalmol. 1964; 71: 238–245
   PubMed Web of Science ®Google Scholar
• McFarlane J. R., Yanoff M., Scheie H. G. Toxic retinopathy following sparsomycin therapy. Arch. Ophthalmol. 1966; 76: 532–540
   PubMed Web of Science ®Google Scholar
• Henkes H. E., van Lith G. H. M., Canta L. R. Indomethacin retinopathy. Am. J. Ophthalmol. 1972; 73: 846–856
   PubMed Web of Science ®Google Scholar
• Davies S. C., Marcus R. E., Hungersford J. L., Miller M. H., Arden G. B., Huehns E. R. Ocular toxicity of high-dose intravenous desferoxamine. Lancet 1983; II: 181–184
   Google Scholar
• Robinson W. G., Jr., Tillis T. N., Laver N., Kinoshita J. H. Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Exp. Eye Res. 1990; 50: 355–366
   PubMed Web of Science ®Google Scholar
• Potts A. M. Toxic responses of the eye. Casaretts and Doulls Toxicology, the Basic Science of Poisons, 3rd ed., C. D. Klaassen, M. O. Amdur, J. Doull. Macmillan, New York 1986; 478–515
   Google Scholar
• Cserr H. F. Physiology of the choroid plexus. Physiol. Rev. 1971; 51: 273–311
   PubMed Web of Science ®Google Scholar
• Benson H. Permeability of the cornea to topically applied drugs. Arch. Ophthalmol. 1974; 91: 313–327
   PubMed Web of Science ®Google Scholar
• Rapoport S. I. Blood-Brain Barrier in Physiology and Medicine. Raven Press, New York 1976
   Google Scholar
• Raviola G. The structural basis of the blood-ocular barriers. Exp. Eye Res. suppl. 1977; 27, 63
   PubMed Web of Science ®Google Scholar
• Mason C. G. Ocular accumulation and toxicity of certain system-ically administered drugs. J. Toxicol. Environ. Health 1977; 2: 977–995
   PubMed Web of Science ®Google Scholar
• Bradbury M. The Concept of the Blood-Brain Barrier. Wiley, Chichester 1979
   Google Scholar
• Bito L. Z., DeRousseau C. J. Transport functions of the blood-retinal barrier system and the microenvironment of the retina. The Blood-Retinal Barriers, J. Cunha-Vaz. Plenum Press, New York 1979; 133–163
   Google Scholar
• Reddy V. N. Dynamics of transport systems in the eye. Invest. Ophthalmol. Vis. Sci. 1979; 18: 1000–1018
   PubMed Web of Science ®Google Scholar
• Burstein N. L. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Survey Ophthalmol. 1980; 25: 15–30
   PubMed Web of Science ®Google Scholar
• Wiederholt M. Physiology of epithelial transport in the human eye. Klin. Wochenschr. 1980; 58: 975–984
   PubMedGoogle Scholar
• Shichi H., Nebert D. W. Drug metabolism in ocular tissues. Extrahepatic Metabolism of Drugs and Other Foreign Compounds, T. E. Gram. S. P. Medical & Scientific Books, New York 1980; 333–363
   Google Scholar
• Zimmerman T. J., Leader B., Kaufman H. E. Advances in ocular pharmacology. Ann. Rev. Pharmacol. Toxicol. 1980; 20: 415–428
   PubMed Web of Science ®Google Scholar
• Mishima S. Clinical pharmacokinetics of the eye. Invest. Ophthalmol. Vis. Sci. 1981; 21: 504–541
   PubMed Web of Science ®Google Scholar
• Shell J. W. Pharmacokinetics of topically applied ophthalmic drugs. Survey Ophthalmol. 1982; 26: 207–218
   PubMed Web of Science ®Google Scholar
• Gjedde A. Modulation of substrate transport to the brain. Acta Neurol. Scand. 1983; 67: 3–25
   PubMed Web of Science ®Google Scholar
• Auricchio G., Libondi T. The physiologic and pharmacologic factors protecting the lens transparency and the update approach to the prevention of experimental cataracts: A review. Metabolic, Pediatric and Systemic Ophthalmology 1983; 7: 115–124
   PubMedGoogle Scholar
• Moller J. V., Sheikh M. I. Renal organic anion transport system: Pharmacological, physiological and biochemical aspects. Pharmacol. Rev. 1983; 34: 315–358
   Web of Science ®Google Scholar
• Mesnil M., Testa B., Jenner P. Xenobiotic metabolism by brain monooxygenases and other cerebral enzymes. Adv. Drug Res. 1984; 13: 95–207
   Google Scholar
• Mathias R. T., Rae J. L. Transport properties of the lens. Am. J. Physiol. 1985; 249: C181–C190
   PubMed Web of Science ®Google Scholar
• Kador P. F., Kinoshita J. H., Sharpless N. E. Aldose reductase inhibitors: A potential new class of agents for the pharmacological control of certain diabetic complications. J. Med. Chem. 1985; 28: 841–849
   PubMed Web of Science ®Google Scholar
• Cornford E. M. The blood-brain barrier, a dynamic regulatory interface. Mol. Physiol. 1985; 7: 219–260
   Google Scholar
• Kador P. F., Robison W. G., Jr., Kinoshita J. H. The pharmacology of aldose reductase inhibitors. Ann. Rev. Pharmacol. Toxicol. 1985; 25: 691–714
   PubMed Web of Science ®Google Scholar
• Koneru P. B., Lien E. J., Koda R. T. Review: Oculotoxicities of systemically administered drugs. J. Ocul. Pharmacol. 1986; 2: 385–404
   PubMedGoogle Scholar
• McLane N. J., Carroll D. M. Ocular manifestations of drug abuse. Survey Ophthalmol. 1986; 30: 298–313
   PubMed Web of Science ®Google Scholar
• Wright C. E., Tallan H. H., Lin Y. Y. Taurine: Biological update. Ann. Rev. Biochem. 1986; 55: 427–453
   PubMed Web of Science ®Google Scholar
• Besseghir K., Roch-Ramel F. Renal excretion of drugs and other xenobiotics. Renal Physiol. 1987; 10: 221–241
   PubMedGoogle Scholar
• Pardridge W. M. Recent advances in blood-brain transport. Ann. Rev. Pharmacol. Toxicol. 1988; 28: 25–39
   PubMed Web of Science ®Google Scholar
• Taylor R., Agius L. The biochemistry of diabetes. Biochem. J. 1988; 250: 625–640
   PubMed Web of Science ®Google Scholar
• Rose R. C. Transport of ascorbic acid and other water-soluble vitamins. Biochim. Biophys. Acta 1988; 947: 335–366
   PubMed Web of Science ®Google Scholar
• Parke D. V. The Biochemistry of Foreign Compounds. Pergamon Press, Oxford 1968
   Google Scholar
• Vaughan D., Asbury T. General Ophthalmology 10th ed. Lange Publications. 1983
   Google Scholar
• Goldman E. Vitalfarbung am Zentralnervensystem. Abhandl. Preuss. Akad. Wiss. Phys.-Math. K. 1913; I: 1–60
   Google Scholar
• Schnaudigel O. Albrecht von Graefes Arch. Ophthalmol. 1913; 86: 93–97, as cited by Cunha-Vaz [85]
   Google Scholar
• Palm E. On the occurrence in the retina of conditions corresponding to the “blood-brain barrier,”. Acta Ophthalmol. 1947; 25: 29–35
   Google Scholar
• Cunha-Vaz J. G., Shakib M., Ashton N. Studies on the permeability of the blood-retinal barrier. I. On the existence, development, and site of a blood-retinal barrier. Brit. J. Ophthalmol. 1966; 50: 441–453
   PubMed Web of Science ®Google Scholar
• Bellhorn R. W. Permeability of blood-ocular barriers of neonatal and adult cat to sodium fluorescein. Invest. Ophthalmol. Vis. Sci. 1980; 19: 870–877
   PubMed Web of Science ®Google Scholar
• Maurice D. M. The use of fluorescein in ophthalmological research. Invest. Ophthalmol. 1967; 6: 464–477
   PubMedGoogle Scholar
• Maurice D. M., Mishima S. Ocular pharmacokinetics. Pharmacology of the Eye, Handbook of Experimental Pharmacology, M. L. Sears. Springer-Verlag, New York 1984; Vol. 69: 19–116
   Google Scholar
• Cunha-Vaz J. Sites and functions of the blood-retinal barriers. The Blood-Retinal Barriers, J. Cunha-Vaz. Plenum Press, New York 1979; 101–117
   Google Scholar
• Newell F. W. Ophthalmology, Principles and Concepts, 6th ed. Mosby. 1986
   Google Scholar
• Betz A. L., Goldstein G. W. Transport of hexoses, potassium and neutral amino acids into capillaries isolated from bovine retina. Exp. Eye Res. 1980; 30: 593–605
   PubMed Web of Science ®Google Scholar
• Crosson C. E., Pautler E. L. Glucose transport across isolated bovine pigment epithelium. Exp. Eye Res. 1982; 35: 371–377
   PubMed Web of Science ®Google Scholar
• Khatami M., Li W., Rockey J. H. Kinetics of ascorbate transport by cultured retinal capillary pericytes. Inhibition by glucose. Invest. Ophthalmol. Vis. Sci. 1986; 27: 1665–1671
   PubMed Web of Science ®Google Scholar
• Khatami M., Stramm L. E., Rockey J. H. Ascorbate transport in cultured cat retinal pigment epithelial cells. Exp. Eye Res. 1986; 43: 607–615
   PubMed Web of Science ®Google Scholar
• Reddy V. N., Thompson M. R., Chakrapani B. Amino acid transport across blood-aqueous barrier of mammalian species. Exp. Eye Res. 1977; 25: 555–562
   PubMed Web of Science ®Google Scholar
• Edwards R. B. Accumulation of taurine by cultured retinal pigment epithelium of the rat. Invest. Ophthalmol. Vis. Sci. 1977; 16: 201–208
   PubMed Web of Science ®Google Scholar
• Kador R F., Jernigan H. M., Jr., Kinoshita J. H. Accumulation and incorporation of radiolabeled choline into cultured rabbit lenses: Evidence for a choline transport system. Exp. Eye Res. 1980; 30: 1–11
   PubMed Web of Science ®Google Scholar
• Walinder R E. The accumulation of alpha-aminoisobutyric acid by rabbit ciliary body-iris preparations. Invest. Ophthalmol. 1968; 7: 67–76
   PubMedGoogle Scholar
• Reddy V. N. Studies on intraocular transport of taurine. I. Accumulation in rabbit ciliary body-iris preparation in vitro. Biochim. Bio-phys. Acta 1968; 158: 246–254
   PubMed Web of Science ®Google Scholar
• Coben L. A., Cotlier E., Beaty C., Becker B. Proline transport by rabbit ciliary body-iris in vitro. Invest. Ophthalmol. 1970; 9: 949–958
   PubMedGoogle Scholar
• Reddy V. N. Transport of organic molecules in the lens. Exp. Eye Res. 1973; 15: 731–750
   PubMed Web of Science ®Google Scholar
• Cotlier E., Beaty C. The transport of 14C-a-aminoisobutyric acid in galactose cataracts in rats and rabbit lenses incubated in high galactose media. Invest. Ophthalmol. 1968; 7: 77–87
   PubMedGoogle Scholar
• Reddy V. N. Studies on intraocular transport of taurine. II. Accumulation in the rabbit lens. Invest. Ophthalmol. 1970; 9: 206–219
   PubMedGoogle Scholar
• Becker B. Ascorbate transport in guinea pig eyes. Invest. Ophthalmol. 1967; 6: 410–415
   Google Scholar
• Chu T. -C., Candia O. A. Active transport of ascorbate across the isolated rabbit ciliary epithelium. Invest. Ophthalmol. Vis. Sci. 1988; 29: 594–599
   PubMed Web of Science ®Google Scholar
• Delamere N. A., Williams R. N. A comparative study on the uptake of ascorbic acid by the iris-ciliary body of the rabbit, guinea pig and rat. Comp. Biochem. Physiol. 1987; 88B: 847–849
   Google Scholar
• Stone R. A. Cholic acid accumulation by the ciliary body and by the iris of the primate eye. Invest. Ophthalmol. Vis. Sci. 1979; 18: 819–826
   PubMed Web of Science ®Google Scholar
• Stone R. A. The transport of para-aminohippuric acid by the ciliary body and by the iris of the primate eye. Invest. Ophthalmol. Vis. Sci. 1979; 18: 807–818
   PubMed Web of Science ®Google Scholar
• Kern H. L. Accumulation of amino acids by calf lens. Invest. Ophthalmol. 1962; 1: 368–376
   PubMedGoogle Scholar
• Varma S. D., Chakrapani B., Reddy V. N. Intraocular transport of myoinositol. II. Accumulation in the rabbit lens in vitro. Invest. Ophthalmol. 1970; 9: 794–800
   PubMedGoogle Scholar
• Shiono T., Kador P. F., Kinoshita J. H. Ornithine accumulation and metabolism in rat lens. Exp. Eye Res. 1985; 40: 421–429
   PubMed Web of Science ®Google Scholar
• DiBenedetto F. E., Bito L. Z. The kinetics and energy dependence of prostaglandin transport processes. I In vitro studies on the rate of PGF2ct accumulation by the rabbit anterior uvea. Exp. Eye Res. 1980; 30: 175–182
   PubMed Web of Science ®Google Scholar
• Socci R. R., Delamere N. A. Characteristics of ascorbate transport in the rabbit iris-ciliary body. Exp. Eye Res. 1988; 46: 853–861
   PubMed Web of Science ®Google Scholar
• Becker B., Forbes M. Iodopyracet (Diodrast) transport by the rabbit eye. Am. J. Physiol. 1961; 200: 461–464
   PubMed Web of Science ®Google Scholar
• Barany E. H. In vitro uptake of bile acids by choroid plexus and anterior uvea. I. The iodipamide-sensitive transport systems in the rabbit. Acta Physiol. Scand. 1975; 93: 250–268
   PubMedGoogle Scholar
• Stone R. A., Wilson C M. Fluorescein transport in the anterior uvea. Invest. Ophthalmol. Vis. Sci. 1982; 22: 303–309
   PubMed Web of Science ®Google Scholar
• Cantrill H. L., Pederson J. E. Experimental retinal detachment. VI. The permeability of the blood-retinal barrier. Arch. Ophthalmol. 1984; 102: 747–751
   PubMed Web of Science ®Google Scholar
• Matsumoto S., Araie M., Takase M. Active transport of beta-adrenergic blocking agents in the anterior uvea of albino rabbit. Japan. J. Ophthalmol. 1986; 30: 339–350
   PubMed Web of Science ®Google Scholar
• Mochizuki M. Transport of indomethacin in the anterior uvea of the albino rabbit. Japan J. Ophthalmol. 1980; 24: 363–373
   Web of Science ®Google Scholar
• Stramm L. E., Pautler E. L. Glucose uptake by normal and dystrophic rat retinas and ciliary bodies. Exp. Eye Res. 1980; 30: 709–718
   PubMed Web of Science ®Google Scholar
• Paterson S. J., Wilson W. S. Uptake of choline by rabbit corneal epithelium. Brit. J. Pharmacol. 1977; 59: 499P
   PubMed Web of Science ®Google Scholar
• Di Mattio J., Zadunaisky J. A. Glucose transport into the ocular compartments of the rat. Exp. Eye Res. 1981; 32: 517–532
   PubMed Web of Science ®Google Scholar
• Di Mattio J. A comparative study of ascorbic acid entry into aqueous and vitreous humors of the rat and guinea pig. Invest. Ophthalmol. Vis. ScL 1989; 30: 2320–2331
   PubMed Web of Science ®Google Scholar
• Kern H. L., Zolot S. L. Transport of vitamin C in the lens. Curr. Eye Res. 1987; 6: 885–896
   PubMed Web of Science ®Google Scholar
• Audus K. L., Borchardt R. T. Transport of macromolecules across the capillary endothelium. Handbook of Experimental Pharmacology, R. L. Juliano. Springer-Verlag, Berlin, in press
   Google Scholar
• Patil P. N. Some factors which affect the ocular drug responses. Trends Pharmacol. Sci. 1984; 5: 201–204
   Web of Science ®Google Scholar
• Schoenwald R. D. Ocular Drug Delivery. Pharmacokinetic Considerations. Clin. Pharmacokinet. 1990; 18: 255–269
   PubMed Web of Science ®Google Scholar
• Piatigorsky J. Lens crystallins and their genes: Diversity and tissue-specific expresion. FASEB J. 1989; 3: 1933–1940
   PubMed Web of Science ®Google Scholar
• Kinsey V. E., Reddy D. V. N. Studies on the crystalline lens. XI. The relative role of the epithelium and capsule in transport. Invest. Ophthalmol. 1965; 4: 104–116
   PubMedGoogle Scholar
• Kern H. L., Ho C. -K., Ostrove S. A. Comparison of transport at the anterior and posterior surfaces of the calf lens. Exp. Eye Res. 1977; 24: 559–570
   PubMed Web of Science ®Google Scholar
• Christensen H. N. Recognition sites for material transport and information transfer. Current Topics in Membranes and Transport, F. Bronner, A. Kleinzeller. Academic Press. 1975; 227–258
   Google Scholar
• Reddy V. N., Varma S. D., Chakrapani B. Intraocular transport of myoinositol. I. Accumulation in rabbit ciliary body. Invest. Ophthalmol. 1970; 9: 785–793
   PubMedGoogle Scholar
• Brassil D., Kern H. L. Characterization of the transport of neutral amino acids by the calf lens. Invest. Ophthalmol. 1968; 7: 441–451
   PubMedGoogle Scholar
• Cotlier E., Myo-inositol. Active transport by the crystalline lens. Invest. Ophthalmol. 1970; 9: 681–691
   PubMedGoogle Scholar
• Reddy V. N., Varma S. D., Chakrapani B. Transport and metabolism of glutathione in the lens. Exp. Eye Res. 1973; 16: 105–114
   PubMed Web of Science ®Google Scholar
• Kern H. L., Ho C. -K. Transport of dicarboxylic amino acids in the rat lens. Ophthal. Res. 1974; 6: 166–174
   Web of Science ®Google Scholar
• Smith E. L., Hill R. L., Lehman I. R., Lefkowitz R. J., Handler P., White E. Principles in Biochemistry–Mammalian Biochemistry, 7th ed. McGraw-Hill. 1983; 663
   Google Scholar
• Downes C. P. The cellular functions of myo-inositol. Biochem. Soc. Trans. 1989; 17: 259–266
   PubMed Web of Science ®Google Scholar
• Maekawa S., Hibasami H., Uji Y., Nakashima K. Active transport and metabolic characteristics of polyamines in the rat lens. Bio-chim. Biophys. Acta 1989; 993: 199–203
   PubMed Web of Science ®Google Scholar
• Reddy D. V. N. Studies on intraocular transport of taurine. I. Accumulation in rabbit ciliary body-iris preparation in vitro. Biochim. Biophys. Acta 1968; 158: 246–254
   PubMed Web of Science ®Google Scholar
• Cayen M. N., Hicks D. R., Ferdinandi E. S., Kraml M., Grese-lin E., Dvornick D. Metabolic disposition and pharmacokinetics of the aldose reductase inhibitor tolrestate in rats, dogs, and monkeys. DrugMetab. Dispos. 1985; 13: 412–419
   PubMed Web of Science ®Google Scholar
• Park Y. H., Woolbridge C. B., Mattern J., Stoltz M. L., Brazzell R. K. Disposition of the aldose reductase inhibitor AL01576. J. Pharm. Sci. 1985; 77: 110–115
   Google Scholar
• Graham D. J. M., Hama K. M., Smith S. A., Kurz L., Chaplin M. D., Hall D. J. Disposition of namfimidone in rats. Drug Me-tabol. Dispos. 1987; 15: 565–570
   PubMed Web of Science ®Google Scholar
• Kobayashi T., Hohnoki H., Esumi Y., Ohtsuki T., Washino T., Tanayama S. Metabolism and disposition of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate (MOTP) in rats and dogs. Xenobiotica 1988; 18: 49–59
   PubMed Web of Science ®Google Scholar
• Tremaine L. M., Welch W. M., Ronfeld R. A. Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug. Metabol. Dispos. 1989; 17: 542–550
   PubMed Web of Science ®Google Scholar
• Potts A. M. The concentration of phenothiazines in the eye of experimental animals. Invest. Ophthalmol. 1962; 1: 522–530
   PubMedGoogle Scholar
• McChesney E. W., Banks W. F., Jr., Sullivan D. J. Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats. Toxicol. Appl. Pharmacol. 1965; 7: 627–636
   PubMed Web of Science ®Google Scholar
• Basu P. K., Matuk Y., Kapur B. M., Avaria M., Jankie R., Carre F. Ocular distribution of sodium pentobarbital after injection of lethal and anesthetic doses and after transfer via corneal grafting. Can. J. Ophthalmol. 1984; 19: 126–129
   PubMed Web of Science ®Google Scholar
• Valeri P., Romanelli L., de Paolis L., Martinelli B. Ocular distribution of aspirin and salicylate following systemic administration of aspirin to rabbits. J. Pharm. Pharmacol. 1988; 40: 823–824
   PubMed Web of Science ®Google Scholar
• Tabbara K. F., O'Connor G. R. Ocular tissue absorption of clindamycin phosphate. Arch. Ophthalmol. 1975; 93: 1180–1185
   PubMed Web of Science ®Google Scholar
• Bloome M. A., Golden B., McKee A. P. Antibiotic concentrations in ocular tissues. Arch. Ophthalmol. 1970; 83: 78–83
   PubMed Web of Science ®Google Scholar
• Fantes F. E., Heuer D. K., Parrish R. K., II, Sossi N., Gressel M. G. Topical fluorouracil–pharmacokinetics in normal rabbit eyes. Arch. Ophthalmol. 1985; 103: 953–955
   PubMed Web of Science ®Google Scholar
• Chen C. C., Anderson J., Shackleton M., Attard J. The disposition of bunolol in the rabbit eye. J. Ocular Pharmacol. 1987; 3: 149–157
   PubMedGoogle Scholar
• Wei C., Anderson J. A., Leopold I. Ocular absorption and metabolism of topically applied epinephrine and a dipivalyl ester of epinephrine. Invest. Ophthalmol. Vis. Sci. 1978; 17: 315–321
   PubMed Web of Science ®Google Scholar
• Wiederholt M., Kossendrup D., Schulz W., Hoffmann F. Pharmacokinetics of topical cyclosporin A in the rabbit eye. Invest. Ophthalmol. Vis. Sci. 1986; 27: 519–524
   PubMed Web of Science ®Google Scholar
• Potts A. M. The reaction of uveal pigment in vitro with polycyclic compounds. Invest. Ophthalmol. 1964; 3: 405–417
   PubMedGoogle Scholar
• Potts A. M. Further studies concerning the accumulation of polycyclic compounds on uveal melanin. Invest. Ophthalmol. 1964; 3: 399–404
   PubMedGoogle Scholar
• Poynter D., Martin L. E., Harrison C., Cook J. Affinity of la-betalol for ocular melanin. Brit. J. Clin. Pharmacol. 1976; 711–721, suppl.
   PubMed Web of Science ®Google Scholar
• Aula P., Kaila T., Huupponen R., Salminen L. Timolol binding to bovine ocular melanin in vitro. J. Ocular Pharmacol. 1988; 4: 29–36
   PubMedGoogle Scholar
• Lyons J. S., Krohn D. L. Pilocarpine uptake by pigmented uveal tissue. Am. J. Ophthalmol. 1973; 75: 885–888
   PubMed Web of Science ®Google Scholar
• Patil P. N., Trendelenburg U. The extraneuronal uptake and metabolism of 3H-isoprenaline in the rabbit iris. Nauyn-Schmiedeberg's Arch. Pharmacol. 1982; 318: 158–165
   PubMed Web of Science ®Google Scholar
• Shimada K., Baweja R., Sokoloski T., Patil P. N. Binding char-actersitics of drugs to synthetic levodopa melanin. J. Pharm. Sci. 1976; 65: 1057–1060
   PubMed Web of Science ®Google Scholar
• Atlasik B., Stepien K., Wilczok T. Interaction of drugs with ocular melanin in vitro. Exp. Eye Res. 1980; 30: 325–331
   PubMed Web of Science ®Google Scholar
• Patil P. N. Cocaine-binding by the pigmented and the nonpigmented iris and its relevance to the mydriatic effect. Invest. Ophthalmol. 1972; II: 739–746
   Google Scholar
• Salazar M., Patil P. N. An explanation for the long duration of mydriatic effect of atropine in the eye. Invest. Ophthalmol. 1976; 15: 671–673
   PubMedGoogle Scholar
• Urtti A., Salminen L., Kujari H., Jantti V. Effect of ocular pigmentation of pilocarpine pharmacology in the rabbit eye. II. Drug response. Int. J. Pharmaceutics 1984; 19: 53–61
   Web of Science ®Google Scholar
• Salminen L., Urtti A., Periviita L. Effect of ocular pigmentation on pilocarpine pharmacology in the rabbit eye. I. Drug distribution and metabolism. Int. J. Pharmaceutics 1984; 18: 17–24
   Web of Science ®Google Scholar
• Obianwu H. O., Rand M. J. The relationship between the mydriatic aeon of aphedrine and the colour of the iris. Brit. J. Ophthalmol. 1965; 49: 264–270
   PubMed Web of Science ®Google Scholar
• Schwartzman M. L., Masferrer J., Dunn M. W., McGiff J. C., Abraham N. G. Cytochrome P-450, drug-metabolizing enzymes and arachidonic acid metabolism in bovine ocular tissues. Curr. Eye Res. 1987; 6: 623–630
   PubMed Web of Science ®Google Scholar
• Sakamoto S., Shichi H. Induction of alkoxyresorufin O-dealkylase and UDP-glucuronosyl transferase by phenobarbital and 3-methylcholanthrene in primary cultures of porcine ciliary epithelial cells. Biochem. Pharmacol., in press
   Web of Science ®Google Scholar
• Das N. D., Shichi H. Enzymes of mercapturate synthesis and other drug-metabolizing reactions–specific localization in the eye. Exp. Eye Res. 1981; 33: 525–533
   PubMed Web of Science ®Google Scholar
• Shichi H., Tsunematsu Y., Nebert D. W. Aryl hydrocarbon hydroxylase induction in retinal pigmented epithelium: Possible association of genetic differences in a drug-metabolizing enzyme system with retinal degeneration. Exp. Eye Res. 1976; 23: 165–176
   PubMed Web of Science ®Google Scholar
• Goos C. M.A. A., Hukkelhoven M. W. A. C., Ver-morken A. J. M., Henderson P. T., Bloemendal H. Metabolism of ben-zo(a)pyrene in bovine lens epithelium. Exp. Eye Res. 1981; 33: 345–350
   PubMed Web of Science ®Google Scholar
• Shichi H., Atlas S. A., Nebert D. W. Genetically regulated aryl hydrocarbon hydroxylase induction in the eye: Possible significance of the drug-metabolizing enzyme system for the retinal pigmented epithelium-choroid. Exp. Eye Res. 1975; 21: 557–567
   PubMed Web of Science ®Google Scholar
• Kishida K., Matsumoto K., Manabe R., Sugiyama T. Cytochrome P-450 and related components of the microsomal electron transport system in the bovine ciliary body. Curr. Eye Res. 1986; 5: 529–533
   PubMed Web of Science ®Google Scholar
• Aimoto T., Chiou G. C. Y. 7-Ethoxycoumarin deethylase activity as indicator of oxidative metabolism in rabbit eyes. J. Ocular Pharmacol. 1985; 1: 279, 286
   PubMedGoogle Scholar
• Gallegos A. J., Partida P. D., Garzon P. The presence of 68-steroid hydroxylase in human cornea. J. Steroid Biochem. 1976; 7: 135–137
   PubMedGoogle Scholar
• Vermorken A. J. M., De R., Waal W. J. M., van De VenBloemendal H., Henderson P. T. Hydroxylation of dehydroepiandros-terone in the eye lens. Biochim. Biophys. Acta 1977; 496: 495–506
   PubMedGoogle Scholar
• Vermorken A. J. M., van de Ven W. J. M., Gielen W. H. J., Bloemendal H., Ketelaars H C.J. Metabolism of dehydroepi-androsterone in the eye lens epithelium. Exp. Eye Res. 1977; 24: 263–270
   PubMedGoogle Scholar
• Abraham N. G., Lin J. H.-C., Dunn M. W., Schwartzman M. Presence of heme oxygenase and NADPH cytochrome P-450(c) reductase in human corneal epithelium. Invest. Ophthalmol. Vis. Sci. 1987; 28: 1464–1472
   PubMed Web of Science ®Google Scholar
• Shanthaveerappa T. R., Bourne G. H. Monoamine oxidase distribution in the rabbit eye. J. Histochem. Cytochem. 1964; 12: 281–287
   PubMed Web of Science ®Google Scholar
• Thomas T. N., Sparks D. L., Buckholtz N. S., Zemp J. W. Monoamine oxidase activity in retina–distribution and drug inhibition. Abstr. Soc. for Neurosci. 1979; 5: 810
   Google Scholar
• Waltman S., Sears M. Catechol-O-methyltransferase and monoamine oxidase activity in the ocular tissues of albino rabbits. Invest. Ophthalmol. 1964; 3: 601–605
   PubMedGoogle Scholar
• Kremzner L. T., Roy D., Spector A. Polyamines in normal and cataractous humans lenses: Evidence for post-translational modification. Exp. Eye Res. 1983; 37: 649–659
   PubMed Web of Science ®Google Scholar
• Crabbe M. J. C. Ocular diamine oxidase activity. Exp. Eye Res. 1985; 41: 777–778
   PubMed Web of Science ®Google Scholar
• Ellis P. P., Littlejohn K., Deitrich R. A. Enzymatic hydrolysis of pilocarpine. Invest. Ophthalmol. 1972; 11: 747–751
   PubMedGoogle Scholar
• Lavallee W. F., Rosenkrantz H. Evidence for pilocarpine transformation by serum. Biochem. Pharmacol. 1966; 15: 206–210
   PubMed Web of Science ®Google Scholar
• Lee V. H. L. Esterase activities in adult rabbit eyes. J. Pharm. Sci. 1983; 72: 239–244
   PubMed Web of Science ®Google Scholar
• Michon J., Jr., Kinoshita J. H. Cholinesterase in the lens. Arch. Ophthalmol. 1967; 77: 804–808
   PubMed Web of Science ®Google Scholar
• Leinweber F. -J. Possible physiological roles of carboxylic ester hydrolases. Drug Metab. Rev. 1987; 18: 379–439
   PubMed Web of Science ®Google Scholar
• Rush R. S., Main A. R., Miller S. K., Kirkpatrick B. F. Resolution and purification of two monomeric butyrylcholine esterases from rabbit liver. J. Biol. Chem. 1980; 255: 7155–7157
   PubMed Web of Science ®Google Scholar
• Billiar R. B., Eiknes K. B. Use of cholinesterase for hydrolysis of steroid acetates. Anal. Biochem. 1965; 13: 11–18
   Web of Science ®Google Scholar
• Mentlein R. The tumor promoter 12-O-tetradecanoyI phorbol 13-acetate and regulatory diacylglycerols are substrates for the same carboxylic esterase. J. Biol. Chem. 1986; 261: 7816–7818
   PubMed Web of Science ®Google Scholar
• Lockridge O., Motthershaw-Jackson N., Eckerson H. W., LaDu B. N. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J. Pharmacol. Exp. Ther. 1980; 215: 1–8
   PubMed Web of Science ®Google Scholar
• Stewart D. J., Inaba T., Tang B. K., Kalow W. Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci. 1977; 20: 1557–1564
   PubMed Web of Science ®Google Scholar
• Main A. R. Purification and properties of plasma cholinesterases. Rev. Biochem. Toxicol. 1984; 6: 117–154
   Google Scholar
• Anderson J. A., Richman J. B., Mindel J. S. Effects of echo-thiophate on enzymatic hydrolysis of dipivefrin. Arch. Ophthalmol. 1984; 102: 913–916
   PubMed Web of Science ®Google Scholar
• Philipson B., Kaufman P. L., Fagerholm P., Axelsson U., Barany E. H. Echothiophate cataracts in monkeys. Arch. Ophthalmol. 1979; 97: 340–346
   PubMed Web of Science ®Google Scholar
• Lockridge O. Substance P hydrolysis by human serum choline-sterase. JNeurochem. 1982; 39: 106–110
   PubMed Web of Science ®Google Scholar
• Boopathy R., Balasubramanian A. S. A peptidase activity exhibited by human pseudocholinesterase. Eur. J. Biochem. 1987; 162: 191–197
   PubMedGoogle Scholar
• Chubb I. W., Hodgson A. J., White G. H. Acetylcholinesterase hydrolyzes substance P. Neuroscience 1980; 5: 2065–2072
   PubMed Web of Science ®Google Scholar
• Chubb I. W., Ranieri E., White G. H., Hodgson A. J. The enkephalins are amongst the peptides hydrolyzed by purified acetylcholinesterase. Neuroscience 1983; 10: 1369–1377
   PubMed Web of Science ®Google Scholar
• Nichols C. W., Koelle G. B. Acetylcholinesterase: Method for demonstration in amacrine cells of rabbit retina. Science 1967; 155: 477–478
   PubMed Web of Science ®Google Scholar
• Petersen R. A., Lee K. -J., Donn A. Acetylcholinesterase in the rabbit cornea. Arch. Ophthalmol. 1965; 73: 370–377
   PubMed Web of Science ®Google Scholar
• Lee V. H. L., Chang S. -C., Oshiro C. M., Smith R. E. Ocular esterase composition in albino and pigmented rabbits: Possible implications in ocular prodrug design and evaluation. Curr. Eye Res. 1985; 4: 1117–1125
   PubMed Web of Science ®Google Scholar
• Moore D. E., Hess G. P. Acetylcholinesterase-catalyzed hydrolysis of an amide. Biochemistry 1975; 14: 2386–2389
   PubMed Web of Science ®Google Scholar
• Hara S., Hayasaka S., Mizuno K. Distribution and some properties of lysosomal arylsulfatases in the bovine eye. Exp. Eye Res. 1979; 28: 641–650
   PubMed Web of Science ®Google Scholar
• Dutton G. J. Glucuronidation of Drugs and Other Compounds. CRC Press, Boca Raton, FL 1966
   Google Scholar
• Hayasaka S., Shiono T. Postnatal changes in lysosomal enzymes of rabbit ocular tissues. Exp. Eye Res. 1982; 34: 571–575
   PubMed Web of Science ®Google Scholar
• Price G., Tsui J., Unakar N. Arylsulfatases in normal and cat-aractous rat lens. Micron 1982; 13: 471–472
   Web of Science ®Google Scholar
• Price G., Tsui J., Unakar N. J. Arylsulfatase–Cytochemical localization in lenses of normal and galactose-fed rats. Curr. Eye Res. 1981/1982; 1: 567–577
   PubMed Web of Science ®Google Scholar
• Harries W., Tsui J., Unakar N. J. Ultrastructural cytochemistry: Effect of Sorbinil on arylsulfatases in cataractous lenses. Curr. Eye Res. 1985; 4: 657–666
   PubMed Web of Science ®Google Scholar
• Tanimoto T., Fukuda H., Kawamura J. Purification and some properties of aldose reductase from rabbit lens. Chem. Pharm. Bull. 1983; 31: 2395–2403
   PubMed Web of Science ®Google Scholar
• Kador P. F., Kinoshita J. H., Brittain D. R., Sennitt C. M., Stribling D., Mirrlees D. J. Purified rat lens aldose reductase. Polyol production in vitro and its inhibition by aldose reductase inhibitors. Biochem. J. 1986; 240: 233–237
   PubMed Web of Science ®Google Scholar
• Okuda J., Miwa I., Inagaki K., Horie T., Nakayama M. Inhibition of aldose reductases from rat and bovine lenses by fla-vonoides. Biochem. Pharmacol. 1982; 31: 3807–3822
   PubMed Web of Science ®Google Scholar
• del Corso A., Barsacchi D., Camici M., Garland D., Mura U. Bovine lens aldose reductase: Identification of two enzyme forms. Arch. Biochem. Biophys. 1989; 270: 604–610
   PubMed Web of Science ®Google Scholar
• Del Corso A., Barsacchi D., Osman A. M., Mohamed A. S., Tozzi M. G., Camici M., Mura U. Lens aldo-keto reductase of Camelus dromedarius: Purification and properties. Biochim. Biophys. Acta 1989; 993: 116–120
   PubMed Web of Science ®Google Scholar
• O'Brien M. M., Schofield P. J. Polyol-pathway enzymes of human brain. Partial purification and properties of aldose reductase and hexonate dehydrogenase. Biochem. J. 1980; 187: 21–30
   PubMed Web of Science ®Google Scholar
• Flynn T. G. Aldehyde reductases: Monomeric NADPH-dependent oxidoreductases with multifunctional potential. Biochem. Pharmacol. 1982; 31: 2705–2712
   PubMed Web of Science ®Google Scholar
• Vander Jagt D. L., Stangebye L. A., Hunsaker L. A., Eaton R. P., Sibbit W. L., Jr. Purification of aldose reductase from human placenta and stabilization of the inhibitor binding site. Biochem. Pharmacol. 1988; 37: 1051–1056
   PubMed Web of Science ®Google Scholar
• von Wartburg J. P., Wermuth B. Aldehyde reductase from human tissues. Meth. Enzymol. 1982; 89: 506–513
   PubMed Web of Science ®Google Scholar
• Sawada H., Hara A., Kato F., Nakayama T. Purification and properties of reductases for aromatic aldehydes and ketones from guinea pig liver. J. Biochem. 1979; 86: 871–881
   PubMed Web of Science ®Google Scholar
• Felsted R. L., Gee M., Bachur N. R. Rat liver daunorubicin reductase, an aldo-keto reductase. J. Biol. Chem. 1974; 249: 3672–3679
   PubMed Web of Science ®Google Scholar
• McMahon R. E. Enzymatic Oxidation of alcohols, aldehydes and ketones. Handbook of Experimental Pharmacology, pt. 2, B. B. Brodie, J. Gillette. Springer-Verlag, New York 1971; vol. 28: 500–517
   Google Scholar
• Bachur N. R. Cytoplasmic aldo-keto reductases: A class of drug-metabolizing enzymes. Science 1976; 193: 595–597
   PubMed Web of Science ®Google Scholar
• Lee V. H. L., Chien D. -S., Sasaki H. Ocular ketone reductase distribution and its role in the metabolism of ocularly applied levobunolol in the pigmented rabbit. J. Pharmacol. Exp. Then 1988; 246: 871–878
   PubMed Web of Science ®Google Scholar
• Woodward D. F., Novack G. D., Williams L. S., Nieves A. L., Potter D. E. Dihydrobunolol is a potent ocular beta-adrenoceptor antagonist. JOcular Pharmacol. 1987; 3: 11–15
   Google Scholar
• Shimada S., Mishima H., Kitamura S., Tatsumi K. Nicotinamide N-oxide reductase activity in bovine and rabbit eyes. Invest. Ophthalmol. Vis. Sci. 1987; 28: 1204–1206
   PubMed Web of Science ®Google Scholar
• Shimada S., Mishima H., Nikaido H., Kitamura S., Tatsumi K. Reduction of drugs by ocular tissue preparations. Abstract I-404-P9, ISSX Meeting, KobeJapan, 1988
   Google Scholar
• Shimada S., Mishima H. K., Nikaido H., Kitamura S., Tatsumi K. Purification of aldehyde oxidase from bovine ciliary body. Curr. Eye Res. 1989; 8: 721–726
   PubMed Web of Science ®Google Scholar
• Shimada S., Mishima H. K., Nikaido H., Kitamura S., Tatsumi K. Metabolism of drugs in the eye. Menadione-dependent reduction of tertiary amine JV-oxide by preparations from bovine ocular tissues. Curr. Eye Res. 1989; 8: 1309–1313
   PubMed Web of Science ®Google Scholar
• Shimada S., Mishima H., Kitamura S., Tatsumi K. Metabolism of drugs in the eye, Drug-reducing activity of preparations from bovine ciliary body. Curr. Eye Res. 1988; 7: 1069–1075
   PubMed Web of Science ®Google Scholar
• Yoshihara S., Tatsumi K. Guinea pig liver aldehyde oxidase as sulfoxide reductase: Its purification and characterization. Arch. Biochem. Biophys. 1985; 242: 213–224
   PubMed Web of Science ®Google Scholar
• Tatsumi K., Yamada H., Kitamura S. Reductive metabolism of A/-nitrosodiphenylamine to the corresponding hydrazine derivative. Arch. Biochem. Biophys. 1983; 226: 174–181
   PubMed Web of Science ®Google Scholar
• Sawada H., Hara A., Hayashibara M., Nakayama T. Guinea pig liver aromatic aldehyde-ketone reductases identical with 17B-hydroxysteroid dehydrogenase isozymes. JBiochem. 1979; 86: 883–892
   Web of Science ®Google Scholar
• Kitamura S., Tatsumi K. Azoreductase activity of liver aldehyde oxidase. Chem. Pharm. Bull. 1983; 31: 3334–3337
   PubMed Web of Science ®Google Scholar
• Tatsumi K., Kitamura S., Narai N. Reductive metabolism of aromatic nitro compounds including carcinogens by rabbit liver preparations. Cancer Res. 1986; 46: 1089–1093
   PubMed Web of Science ®Google Scholar
• Sugihara K., Tatsumi K. Participation of liver aldehyde oxidase in reductive metabolism of hydroxamic acids to amides. Arch. Biochem. Biophys. 1986; 247: 289–293
   PubMed Web of Science ®Google Scholar
• Shichi H., O'Meara R D. Purification and properties of anionic glutathione ^-transferase from bovine ciliary body. Biochem. J. 1986; 237: 365–371
   PubMed Web of Science ®Google Scholar
• Saneto R. R, Awasthi Y. C., Srivastava S. K. Glutathione S-transferases of the bovine retina. Biochem. J. 1982; 205: 213–217
   PubMed Web of Science ®Google Scholar
• Singh S. V., Dao D. D., Srivastava S. K., Awasthi Y. C. Purification and characterization of glutathione ^-transferases in human retina. Curr. Eye Res. 1984; 3: 1273–1280
   PubMed Web of Science ®Google Scholar
• Awasthi Y. C., Saneto R. P., Srivastava S. K. Purification and properties of bovine lens glutathione S-transferase. Exp. Eye Res. 1980; 30: 29–39
   PubMed Web of Science ®Google Scholar
• Saneto R. P., Awasthi Y. C., Srivastava S. K. Interrelationship between cationic and anionic forms of glutathione S-transferases of bovine ocular lens. Biochem. J. 1980; 191: 11–20
   PubMed Web of Science ®Google Scholar
• Singh S. V., Hong T. D., Srivastava S. K., Awasthi Y. C. Characterization of glutathione 5-transferases of human cornea. Exp. Eye Res. 1985; 40: 431–437
   PubMed Web of Science ®Google Scholar
• Das N. D., Shichi H. Gamma-glutamyl transpeptidase of bovine ciliary body: Purification and properties. Exp. Eye Res. 1979; 29: 109–121
   PubMed Web of Science ®Google Scholar
• Reddy V. N., Unakar N. J. Localization of gamma-glutamyl transpeptidase in rabbit lens, ciliary process and cornea. Exp. Eye Res. 1973; 17: 405–408
   PubMed Web of Science ®Google Scholar
• Ng M. C., Shichi H. Enzymes of mercapturate pathway in cultured bovine ciliary epithelial cells. J. Ocular Pharmacol. 1987; 3: 341–348
   PubMedGoogle Scholar
• Kishida K., Akaki Y., Sasabe T., Yamamoto C., Manabe R. Glutathione conjugation of methazolamide and subsequent reactions in the ciliary body in vitro. J. Pharm. Sci. 1990; 79: 638–642
   PubMed Web of Science ®Google Scholar
• Hotta N., Kakuta H., Ando F., Sakamoto N. Current progress in clinical trials of aldose reductase inhibitors in Japan. Exp. Eye Res. 1990; 50: 625–628
   PubMed Web of Science ®Google Scholar
• Mizuno K. Studies on retinitis pigmentosa. Eye, Ear, Nose and Throat Monthly 1960; 39: 493–499
   PubMedGoogle Scholar
• Putnam M. L., Schoenwald R. D., Duffel M. W., Bar-fknecht C. F., Segarra T. M., Campbell D. A. Ocular disposition of aminozolamide in the rabbit eye. Invest. Ophthalmol. Vis. Sci. 1987; 28: 1373–1382
   PubMed Web of Science ®Google Scholar
• Patil P. N., Trendelenburg U. The extraneuronal uptake and metabolism of 3H-isoprenaline in the rabbit iris. Naunyn-Schmiedeberg's Arch. Pharmacol. 1982; 318: 158–165
   Google Scholar
• Jedziniak J. A., Kinoshita J. H. Activators and inhibitors of lens aldose reductase. Invest. Ophthalmol. 1971; 10: 357–366
   PubMedGoogle Scholar
• Fukushi S., Merola S., Kinoshita J. H. Altering the course of cataracts in diabetic rats. Invest. Ophthalmol. Vis.5c J. 1980; 19: 313–315
   PubMed Web of Science ®Google Scholar
• Beyer-Mears A., Cruz E., Nicolas-Alexandre J., Varagiannis E. Sorbinil protection of lens components and cell hydration during diabetic cataract formation. Pharmacology 1982; 24: 193–200
   PubMed Web of Science ®Google Scholar
• Hu T. -S., Datiles M., Kinoshita J. H. Reversal of galactose cataract with sorbinil in rats. Invest. Ophthalmol. Vis. Sci. 1983; 24: 640–644
   PubMed Web of Science ®Google Scholar
• Jacobson M., Sharma Y. R., Cotlier E., Hollander J. D. Diabetic complications in lens and nerve and their prevention by sulin-dac or sorbinil: two novel aldose reductase inhibitors. Invest. Ophthalmol. Vis. Sci. 1983; 24: 1426–1429
   PubMed Web of Science ®Google Scholar
• Hu T. -S., Merola L. O., Kuwabara T., Kinoshita J. H. Prevention and reversal of galactose cataract in rats with topical sorbinil. Invest. Ophthalmol. Vis. Sci. 1984; 25: 603–605
   PubMed Web of Science ®Google Scholar
• Okuda J., Yashima K., Inagaki K., Miwa I. Effects of an aldose reductase inhibitor, l-[(p-bromophenyl)sulfonyl]hydantoin, on cataract formation and tissue polyol levels in galactosemic rats. Chem. Pharm. Bull. 1985; 33: 2990–2995
   PubMed Web of Science ®Google Scholar
• Beyer-Mears A., Cruz E. Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor. Diabetes 1985; 34: 15–21
   PubMed Web of Science ®Google Scholar
• Simard-Duquesne N., Greselin E., Gonzalez R., Dvornik D. Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, tolrestate (42048). Proc. Soc. Exp. Biol. Med. 1985; 178: 599–605
   PubMed Web of Science ®Google Scholar
• Unakar N., Tsui J., Johnson M. Aldose reductase inhibitors and prevention of galactose cataracts in rats. Invest. Ophthalmol. Vis. Sci. 1989; 30: 1623–1632
   PubMed Web of Science ®Google Scholar
• Lou M. F., Dickerson J. E., Jr., Handler M. L., Brazzell R. K., York B. M. The prevention of biochemical changes in lens, retina and nerve of galactosemic dogs by the aldose reductase inhibitor AL01576. J. Ocular Pharmacol. 1989; 5: 233–240
   PubMedGoogle Scholar
• Varma S. D., Schocket S. S., Richards R. D. Implications of aldose reductase in cataracts in human diabetes. Invest. Ophthalmol. Vis. Sci. 1979; 18: 237–241
   PubMed Web of Science ®Google Scholar
• Crabbe M. J. C., Petchey M., Burgess S. E. P., Cheng H. The penetration of sorbinil, an aldose reductase inhibitor, into lens, aqueous humor and erythrocytes of patients undergoing cataract extraction. Exp. Eye Res. 1985; 40: 95–99
   PubMed Web of Science ®Google Scholar
• Kador P. F. Overview of the current attempts toward the medical treatment of cataract. Ophthalmology 1983; 90: 352–364
   PubMed Web of Science ®Google Scholar
• Hara A., Harado T., Kakagawa M., Matsuura M., Nakayama T., Sawada H. Isolation from the pig lens of two proteins with dihydrodiol dehydrogenase and aldehyde reductase activities. Bio-chem. J. 1989; 264: 403–407
   PubMed Web of Science ®Google Scholar
• Stribling D. Clinical trials with aldose reductase inhibitors. Exp. Eye Res. 1990; 50: 621–624
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J. G., Maurice D. M. The active transport of fluorescein by the retinal vessels and the retina. J. Physiol. 1967; 191: 467–486
   Google Scholar
• Blair N. P., Zeimer R. C., Rusin M. M., Cunha-Vaz J. G. Outward transport of fluorescein from the vitreous in normal human subjects. Arch. Ophthalmol. 1983; 101: 1117–1121
   PubMed Web of Science ®Google Scholar
• Cole D. F. Aqueous and ciliary body. Biochemistry of the Eye, C. N. Graymore. Academic Press, London 1970; 105–181
   Google Scholar
• Bito L. Z., Salvador E. V. Effects of anti-inflammatory agents and some other drugs on prostaglandin biotransport. J. Pharmacol. Exp. Ther. 1976; 198: 481–488
   PubMed Web of Science ®Google Scholar
• Bito L. Z. Absorptive transport of prostaglandins from intraocular fluids to blood: A review of recent findings. Exp. Eye Res. 1973; 16: 299–306
   PubMed Web of Science ®Google Scholar
• Bito L. Z., Wallenstein M. C. Transport of prostaglandins across the blood-brain and blood-aqueous barriers and the physiological significance of these absorptive transport processes. Exp. Eye Res. 1977; 25: 229–243, suppl.
   PubMed Web of Science ®Google Scholar
• Bito L. Z., Salvador E. V. Intraocular fluid dynamics. III. The site and mechanism of prostaglandin transfer across blood intraocular fluid barriers. Exp. Eye Res. 1972; 14: 233–241
   PubMed Web of Science ®Google Scholar
• Eakins K. E., Atwal M., Bhattacherjee P. Inactivation of prostaglandin E, by ocular tissues in vitro. Exp. Eye Res. 1974; 19: 141–146
   PubMed Web of Science ®Google Scholar
• Bito L. Z., Baroody R. Concentrative accumulation of 3H-prostaglandins by some rabbit tissues in vitro: The chemical nature of the accumulated 3H-labelled substances. Prostaglandins 1974; 7: 131–140
   PubMed Web of Science ®Google Scholar
• Bito L. Z. Prostaglandins and related compounds as potential ocular therapeutic agents. Biological Protection with Prostaglandins. CRC Press, Boca Raton, FL 1987; vol. 1: 231–252
   Google Scholar
• Bito L. Z. Eicosanoid transport system: Mechanisms, Physiological roles, and inhibitors. CRC Handbook of Eicosanoids: Pros-taglandins and Related Lipids. CRC Press, Boca Raton, FL 1987; vol. 1: 211–231
   Google Scholar
• Bito L. Z. Prostaglandins and other eicosanoids: Their ocular transport, pharmacokinetics, and therapeutic effects. Trans. Ophthalmol. Soc. UK 1986; 105: 162–170
   PubMedGoogle Scholar
• Bito L. Z. Absorptive transport of prostaglandins and other eicosanoids across the blood-brain barrier system and its physiological significance. Blood-Brain Barrier in Health and Disease, M. Bradbury, M. G. Rumsby, A. J. Suckling. Ellis Horwood Ltd. 1985; 109–121
   Google Scholar
• Maurice D. M. Drug exchanges between the blood and vitreous. The Blood-Retinal Barriers, J. G. Cunha-Vaz. Plenum Press. 1979; 165–178
   Google Scholar
• Reddy V. N., Chakrapany B., Lim C. P. Blood-vitreous barrier to amino acids. Exp. Eye Res. 1977; 25: 543–554
   PubMed Web of Science ®Google Scholar
• Barza M., Kane A., Baum J. The effects of infection and probenecid on the transport of carbenicillin from the rabbit vitreous humor. Invest. Ophthalmol. Vis. Sci. 1982; 22: 720–726
   PubMed Web of Science ®Google Scholar
• Salminen L., Jarvinen H., Toivanen P. Distribution of tritiated benzylpenicillin in the rabbit eye. Invest. Ophthalmol. Vis. Sci. 1969; 47: 115–121
   Google Scholar
• Faris B. M., Uwaydah M. W. Intraocular penetration of semisynthetic penicillins. Arch. Ophthalmol. 1974; 92: 501–505
   PubMed Web of Science ®Google Scholar
• Reddy V. N., Thompson M. R., Chakrapani B. Amino acid transport across blood-aqueous barrier of mammalian species. Exp. Eye Res. 1977; 25: 555–562
   PubMed Web of Science ®Google Scholar
• Furguiele F. P., Smith J. P., Baron J. G. Tobramycin levels in human eyes. Am. J. Ophthalmol. 1978; 85: 121–123
   PubMed Web of Science ®Google Scholar
• Oldendorf W. H. Lipid solubility and drug penetration of the blood-brain barrier. Proc. Soc. Exp. Biol. Med. 1974; 147: 813–816
   PubMed Web of Science ®Google Scholar
• Rapoport S. I., Ohno K., Pettigrew K. D. Drug entry into the brain. Brain Res. 1979; 172: 354–359
   PubMed Web of Science ®Google Scholar
• Levin V. A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 1980; 23: 682–684
   PubMed Web of Science ®Google Scholar
• Cornford E. M., Braun L. D., Oldendorf W. H., Hill M. A. Comparison of lipid-mediated blood-brain penetrability in neonates and adults. Am. J. Physiol. 1982; 243: C161–C168
   PubMed Web of Science ®Google Scholar
• Reese T. S., Karnovsky M. J. Fine Structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 1967; 34: 207–217
   PubMed Web of Science ®Google Scholar
• Goldstein G. W., Betz A. L., Bowman P. D., Dorovini-Zis K. In vitro, studies of the blood-brain barrier using isolated brain capillaries and cultured endothelial cells. Ann. NY Acad. Sci. 1986; 481: 202–213
   PubMed Web of Science ®Google Scholar
• Bito L., Davson H., Levin E., Murray M., Snider N. The concentrations of free amino acids and other electrolytes in cerebrospinal fluid in vivo dialysate of brain, and blood plasma of the dog. J. Neurochem. 1966; 13: 1057–1057
   PubMed Web of Science ®Google Scholar
• Pollay M., Davson H. The passage of certain substances out of the cerebrospinal fluid. Brain 1963; 86: 137–150
   PubMed Web of Science ®Google Scholar
• Davson H., Kleeman C. R., Levin E. Quantitative studies of the passage of different substances out of the cerebrospinal fluid. J. Physiol. 1962; 161: 126–142
   PubMed Web of Science ®Google Scholar
• Pardridge W. M. Blood-brain barrier transport of nutrients. Fed. Proc 1986; 45: 2047–2049
   PubMedGoogle Scholar
• Spector R. Micronutrient homeostasis in mammalian brain and cerebrospinal fluid. J. Neurochem. 1989; 53: 1667–1674
   PubMed Web of Science ®Google Scholar
• Oldendorf W. H. Brain uptake of radiolabeled amino acids, amines and hexoses after arterial injection. Am. J. Physiol. 1971; 221: 1629–1639
   PubMed Web of Science ®Google Scholar
• Oldendorf W. H., Szabo J. Amino acid assignment to one of three blood-brain barrier amino acid carriers. Am. J. Physiol. 1976; 230: 94–98
   PubMed Web of Science ®Google Scholar
• Pardridge W. M. Kinetics of competitive inhibition of neutral amino acid transport across the blood-brain barrier. J. Neurochem. 1977; 28: 103–108
   PubMed Web of Science ®Google Scholar
• Pardridge W. M., Oldendorf W. H. Kinetic analysis of blood-brain barrier transport of amino acids. Biochim. Biophys. Acta 1975; 401: 128–136
   PubMed Web of Science ®Google Scholar
• Pardridge W. M., Connor J. D. Saturable transport of amphetamine across the blood-brain barrier. Experientia 1973; 29: 302–304
   PubMedGoogle Scholar
• Markovitz D. C., Fernstrom J. D. Diet and uptake of aldomet by the brain: Competition with natural large neutral amino acids. Sci-ence 1977; 197: 1014–1015
   PubMed Web of Science ®Google Scholar
• Greig N. H., Momma S., Sweeney D. J., Smith Q. R., Rapoport S. I. Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. Cancer Res. 1987; 47: 1571–1576
   PubMed Web of Science ®Google Scholar
• Cornford E. M., Braun L. D., Oldendorf W. H. Carrier mediated blood-brain barrier transport of choline and certain choline analogs. J. Neurochem. 1978; 30: 299–308
   PubMed Web of Science ®Google Scholar
• Greenwood J., Love E. R., Pratt O. E. Kinetics of thiamine transport across blood-brain barrier in the rat. J. Physiol. 1982; 327: 95–KB
   PubMed Web of Science ®Google Scholar
• Becker B. The transport of organic anions by the rabbit eye. I” In vitro iodopyracet (Diodrast) accumulation by ciliary body-iris preparations. Am. J. Ophthalmol. 1960; 50: 862–867
   PubMed Web of Science ®Google Scholar
• Forbes M., Becker B. The transport of organic anions by the rabbit eye. II”In vivo transport of iodopyracet (Diodrast). Am. J. Ophthalmol. 1960; 50: 867–873
   PubMed Web of Science ®Google Scholar
• Becker B. Cerebrospinal fluid iodide. Am. J. Physiol. 1961; 201: 1149–1151
   PubMed Web of Science ®Google Scholar
• Barany E. H. Inhibition by hippurate and probenecid of in vitro uptake of iodipamide and o-iodohippurate. A composite uptake system for iodipamide in choroid plexus, kidney cortex and anterior uvea of several species. Acta Physiol. Scand. 1972; 86: 12–27
   PubMedGoogle Scholar
• Barany E. H. The liver-like anion transport system in rabbit kidney, uvea and choroid plexus. I. Selectivity of some inhibitors, direction of transport, possible physiological substrates. Acta Physiol. Scand. 1973; 88: 412–429
   PubMedGoogle Scholar
• Barany E. H. The liver-like anoin transport system in rabbit kidney, uvea and choroid plexus. II. Efficiency of acidic drugs and other anions as inhibitors. Acta Physiol. Scand. 1973; 88: 491–504
   PubMedGoogle Scholar
• Lorenzo A. V., Cutler R. W. P. Amino acid transport by choroid plexus in vitro. J. Neurochem. 1969; 16: 577–585
   PubMed Web of Science ®Google Scholar
• Coben L. A., Cotlier E., Beaty C., Becker B. Transport of amino acids by rabbit choroid plexus in vitro. Brain Res. 1971; 30: 67–82
   PubMed Web of Science ®Google Scholar
• Csaky T. Z., Rigor B. M., Sr. A concentrative mechanism for sugars in the choroid plexus. Life Sci. 1964; 3: 931–936
   PubMed Web of Science ®Google Scholar
• Spector R., Lorenzo A. V. Specificity of ascorbic acid transport system of the central nervous system. Am. J. Physiol. 1974; 226: 1468–1473
   PubMed Web of Science ®Google Scholar
• Berlin R. D., Purines. Active transport by isolated choroid plexus. Science 1969; 163: 1194–1195
   PubMed Web of Science ®Google Scholar
• Bdrany E. H. Organic cation uptake in vitro by the rabbit iris-ciliary body, renal cortex, and choroid plexus. Invest. Ophthalmol. 1976; 15: 341–349
   PubMedGoogle Scholar
• Di Benedetto F. E., Bito L. Z. Transport of prostaglandins and other eicosanoids by the choroid plexus: Its characterization and physiological significance. J. Neurochem. 1986; 46: 1725–1731
   PubMed Web of Science ®Google Scholar
• Fishman R. A. Blood-brain and CSF barriers to penicillin and related organic acids. Arch. Neurol. 1966; 15: 113–124
   PubMed Web of Science ®Google Scholar
• Pappenheimer J. R., Heisey S. R., Jordan E. F. Active transport of diodrast and phenolsulfonphthalein from cerebrospinal fluid to blood. Am. J. Physiol. 1961; 200: 1–10
   PubMed Web of Science ®Google Scholar
• Cornford E. M., Diep C. P., Pardridge W. M. Blood-brain barrier transport of valproic acid. J. Neurochem 1985; 44: 1541–1550
   PubMed Web of Science ®Google Scholar
• Oldendorf W. H., Hyman S., Braun L., Oldendorf S. Z. Blood-brain barrier: Penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 1972; 178: 984–986
   PubMed Web of Science ®Google Scholar
• Bito L. Z., Davson H., Hollingsworth J. R. Facilitated transport of prostaglandins across the blood-cerebrospinal fluid and blood-brain barriers. J. Physiol. 1976; 256: 273–285
   PubMed Web of Science ®Google Scholar
• Spector R., Goetzl E. J. Leukotriene C4 by the choroid plexus in vitro. Science 1985; 228: 325–327
   PubMed Web of Science ®Google Scholar
• Spector R., Goetzl E. J. Leukotriene C4 transport and metabolism in the central nervous system. J. Neurochem. 1986; 46: 1308–1312
   PubMed Web of Science ®Google Scholar
• Spector R., Lorenzo A. V. Folate transport by the choroid plexus in vitro. Science 1975; 187: 540–542
   PubMed Web of Science ®Google Scholar
• Cserr H. F., van Dyke D. H. 5-Hydroxyindoleacetic acid accumulation by isolated choroid plexus. Am. J. Physiol. 1971; 220: 718–723
   PubMed Web of Science ®Google Scholar
• Forn J. Active transport of 5-hydroxyindoleacetic acid by the rabbit choroid plexus in vitro. Biochem. Pharmacol. 1972; 21: 619–624
   PubMed Web of Science ®Google Scholar
• Meek J. L., Neff H. N. Acidic and neutral metabolites of norepinephrine: Their metabolism and transport from brain. J. Pharmacol. Exp. Ther. 1972; 181: 457–462
   PubMed Web of Science ®Google Scholar
• Hug C. C., Jr. Transport of narcotic analgesics by choroid plexus and kidney tissue in vitro. Biochem. Pharmacol. 1967; 16: 345–359
   PubMed Web of Science ®Google Scholar
• Wang J. H., Takemori A. E. Studies on the transport of morphine into the cerebrospinal fluid of rabbits. J. Pharmacol. Exp. Ther. 1972; 183: 41–48
   PubMed Web of Science ®Google Scholar
• Huang J. T., Takemori A. E. Accumulation of methadone by the choroid plexus in vitro. Neuropharmacol. 1975; 14: 214–246
   Google Scholar
• Tochino Y., Schanker L. S. Active transport of quaternary ammonium compounds by the choroid plexus in vitro. Am. J. Physiol. 1965; 208: 666–673
   PubMed Web of Science ®Google Scholar
• Pritchard J. B. Accumulation of anionic pesticides by rabbit choroid plexus in vitro. J. Pharmacol. Exp. Ther. 1980; 212: 354–359
   PubMed Web of Science ®Google Scholar
• Kim C. S., O'Tuama L. A., Mann J. D., Roe C. R. Saturable accumulation of the anionic herbicide, 2, 4-dichlorophenoxyacetic acid (2,4-D) by rabbit choroid plexus: Early developmental origin and interaction with salicylates. J. Pharmacol. Exp. Ther. 1983; 225: 699–704
   PubMed Web of Science ®Google Scholar
• Suzuki H., Sawada Y., Sugiyama Y., Iga T., Hanano M. Transport of cimetidine by the rat choroid plexus in vitro. J. Pharmacol. Exp. Ther. 1986; 239: 927–935
   PubMed Web of Science ®Google Scholar
• Suzuki H., Sawada Y., Sugiyama Y., Iga T., Hanano M. Transport of benzylpenicillin by the rat choroid plexus in vitro. J. Pharmacol. Exp. Ther. 1987; 242: 660–665
   PubMed Web of Science ®Google Scholar
• Nohjoh T., Suzuki H., Sawada Y., Sugiyama Y., Iga T., Hanano M. Transport of cefodizime, a novel third-generation cephalosporin anitbiotic, in isolated rat choroid plexus. J. Pharmacol. Exp. Ther. 1989; 250: 324–328
   PubMed Web of Science ®Google Scholar
• Bigley R., Wirth M., Layman D., Stankova L. Interaction between glucose and dehydroascorbate transport in human neutrophils and fibroblasts. Diabetes 1983; 32: 545–548
   PubMed Web of Science ®Google Scholar
• Hjelle J. T., Baird-Lambert J., Cardinale G., Spector S., Udenfriend S. Isolated microvessels: The blood-brain barrier in vitro. Proc. Natl. Acad. Sci. USA 1978; 75: 4544–4548
   PubMed Web of Science ®Google Scholar
• Betz A. L., Goldstein G. W. Polarity of the blood-brain barrier: Neutral amino acid transport into isolated brain capillaries. Science 1978; 202: 225–226
   PubMed Web of Science ®Google Scholar
• Goldstein G. W., Wolinski J. S., Csejtey J., Diamond I. Isolation of metabolically active capillaries from rat brain. J. Neuro-chem. 1975; 25: 715–717
   PubMed Web of Science ®Google Scholar
• Goldstein G. W., Betz A. L., Bowman P. D. Use of isolated brain capillaries and cultured endothelial cells to study the blood-brain barrier. Fed. Proc 1984; 43: 191–195
   PubMedGoogle Scholar
• van Bree J. B. M. M., DeBoer A. G., Danhof M., Ginsel L. A., Breimer D. D. Characterization of an “in vitro” blood-brain barrier: Effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J. Pharmacol. Exp. Ther. 1988; 247: 1233–1239
   PubMed Web of Science ®Google Scholar
• De Bault L. E., Kahn L. E., Frommes S. P., Cancilla P. A. Cerebral microvessels and derived cells in tissue culture: Isolation and preliminary characterization. In Vitro 1979; 15: 473–487
   PubMedGoogle Scholar
• Audus K. L., Borchardt R. T. Characteristics of the large neutral amino acid transport system of bovine microvessel endothelial cell monolayers. J. Neurochem. 1986; 47: 484–488
   PubMed Web of Science ®Google Scholar
• Bowman P. D., Betz A. L., Ar D., Wolinski J. S., Penney J. B., Shivers R. R., Goldstein G. W. Primary culture of capillary endothelium from rat brain. In Vitro 1981; 17: 353–362
   PubMedGoogle Scholar
• Hargreaves K. M., Pardridge W. M. Neutral amino acid transport at the human blood-brain barrier. J. Biol. Chem. 1988; 263: 19392–19397
   PubMed Web of Science ®Google Scholar
• Kishi M., Ohkuma S., Kimori M., Kuriyama K. Characteristics of taurine transport system and its developmental pattern in mouse cerebral cortical neurons in primary culture. Biochim. Bio-phys. Acta 1988; 939: 615–623
   PubMed Web of Science ®Google Scholar
• Tayarani I., Cloez I., Lefauconnier J. -M., Bourre J. -M. Sodium-dependent high-affinity uptake of taurine by isolated rat brain capillaries. Biochim. Biophys. Acta 1989; 985: 168–172
   PubMed Web of Science ®Google Scholar
• van Bree J. B. M. M., Audus K. L., Borchardt R. T. Carrier-mediated transport of baclofen across monolayers of bovine brain endothelial cells in primary culture. Pharmaceut. Res. 1988; 5: 369–371
   PubMed Web of Science ®Google Scholar
• Wu P. H., Phillis J. W. Uptake of adenosine by isolated rat brain capillaries. J. Neurochem. 1982; 38: 687–690
   PubMed Web of Science ®Google Scholar
• Ghersi-Egea J. -F., Minn A., Siest G. A new aspect of the protective functions of the blood-brain barrier: Activities of four drug-metabolizing enzymes in isolated rat brain microvessels. Life Sci. 1988; 42: 2515–2523
   PubMed Web of Science ®Google Scholar
• Baranczyk-Kuzma A., Audus K. L., Borchardt R. T. Catecholamine-metabolizing enzymes of bovine brain microvessel endothelial cell monolayers. J. Neurochem. 1986; 46: 1956–1960
   PubMed Web of Science ®Google Scholar
• Deuticke B. Monocarboxylate transport in red blood cells: Kinetics and chemical modification. Meth. Enzymol. 1989; 173: 732–745
   PubMedGoogle Scholar
• Kaplan R. S., Pratt R. D., Pedersen P. L. Purification and re-constitution of the phosphate transporter from rat liver. Meth. Enzymol. 1989; 173: 732–745
   PubMed Web of Science ®Google Scholar
• Goldinger J. M., Khalsa B. D. S., Hong S. K. Photoaffinity labeling of organic anion transport system in proximal tubule. Am. J. Physiol. 1984; 247: C217–C227
   PubMed Web of Science ®Google Scholar
• Wolkoff A. W., Chung C. T. Identification, purification and partial characterization of an organic anion binding protein from rat liver cell plasma membrane. J. Clin. Invest. 1980; 65: 1152–1161
   PubMed Web of Science ®Google Scholar
• Stremmel W., Gerber M. A., Glezerov V., Thung S. N., Kochwa S., Berk P. D. Physiocochemical and immunohistologi-cal studies of a sulfobromophthalein-and bilirubin-binding protein from rat liver plasma membranes. J. Clin. Invest. 1983; 71: 1796–1805
   PubMedGoogle Scholar
• Reichen J., Berk P. D. Isolation of an organic anion binding protein from rat liver plasma membrane fraction by affinity chromatography. Biochem. Biophys. Res. Commun. 1979; 91: 484–489
   PubMed Web of Science ®Google Scholar
• Dick A. P. K., Harik S. I., Klip A., Walker D. M. Identification and characterization of the glucose transporter of the blood-brain barrier by cytochalasin B binding and immunological reactivity. Proc. Natl. Acad. Sci. USA 1984; 81: 7233–7237
   PubMed Web of Science ®Google Scholar
• Baldwin S. A., Cairns M. T., Gardiner R. M., Ruggier R. A D-glucose-sensitive cytochalasin B binding component of cerebral microvessels. J. Neurochem. 1985; 45: 650–652
   PubMed Web of Science ®Google Scholar
• Suleiman S. A., Spector R. Purification and characterization of a folate binding protein from porcine choroid plexus. Arch. Biochem. Biophys. 1981; 208: 87–94
   PubMed Web of Science ®Google Scholar
• Loscher W., Nau H. Distribution of valproic acid and its metabolites in various brain areas of dogs and rats and after acute and prolonged treatment. J. Pharmacol. Exp. Then 1983; 226: 845–854
   PubMed Web of Science ®Google Scholar
• Neff N., Rossi G. V., Chase G. D., Rabinowitz J. L. Distribution and metabolism of mescaline-C14 in the cat brain. J. Pharmacol. Exp. Ther. 1964; 144: 1–7
   PubMed Web of Science ®Google Scholar
• Snyder S. H., Reivich M. Regional localization of lysergic acid diethylamide in monkey brain. Nature 1966; 209: 1093–1095
   PubMed Web of Science ®Google Scholar
• Martin B. R., Dewey W. L., Harris L. S., Beckner J. S. 3H-A9-tetrahydrocannabinol tissue and subcellular distribution in the CNS and tissue distribution in peripheral organs of tolerant and non-tolerant dogs. J. Pharmacol. Exp. Ther. 1976; 196: 128–144
   PubMed Web of Science ®Google Scholar
• Sershen H., Reith M. E. A., Hashim A., Lajtha A. Comparison of [3H]nicotine and [3H]acetylcholine binding in mouse brain: Regional distribution. Res. Commun. Chem. Pathol. Pharmacol. 1985; 48: 345–352
   PubMedGoogle Scholar
• Mohler H., Okada T., Heitz P., Ulrich J. Biochemical identification of the site of action of benzodiazepines in human brain by 3H-diazepam binding. Life Sci. 1978; 22: 985–996
   PubMed Web of Science ®Google Scholar
• Young W. S.HI, Kuhar M. J. Radiochemical localization of benzodiazepine receptors in rat brain. J. Pharmacol. Exp. Ther. 1980; 212: 337–346
   PubMed Web of Science ®Google Scholar
• Kim C., Speisky M. B., Kalant H. Simultaneous determination of biogenic amines and morphine in discrete rat brain regions by high performance liquid chromatography with electrochemical detection. J. Chromatog. 1986; 370: 303–313
   PubMed Web of Science ®Google Scholar
• Agnew W. F., Rumbaugh C. L., Cheng J. T. The uptake of A9-tetrahydrocannabinol in choroid plexus and brain cortex in vitro and in vivo. Brain Res. 1976; 109: 355–366
   PubMed Web of Science ®Google Scholar
• Shah N. S., Powell D. A., Shahi A. B., Wiscovitch R., McAmis W. Distribution of 3H-levo-cocaine in brain regions of rabbit after intracerebroventricular administration. Res. Commun. Subst. Abuse 1982; 3: 433–441
   Google Scholar
• Minder R., Schnetzer F., Bickel M. H. Hepatic and extrahepatic metabolism of the psychotropic drugs, chlorpromazine, imipramine and imipramine N-oxide. Naunyn-Schmiedebergs Arch. Pharmakol. 1971; 268: 334–347
   PubMedGoogle Scholar
• Dingell J. V., Sulser F., Gillette J. R. Species differences in the metabolism of imipramine and desmethylimipramine. J. Pharmacol. Exp. Ther. 1964; 143: 14–22
   PubMed Web of Science ®Google Scholar
• Machinist J. M., Dehner E. W., Ziegler D. M. Microsomal oxidases. III. Comparison of species and organ distribution of dialky-larylamine N-oxide dealkylase and dialkylarylamine JV-oxidase. Arch. Biochem. Biophys. 1968; 125: 858–864
   PubMed Web of Science ®Google Scholar
• Uehleke H. Extrahepatic microsomal drug metabolism. Proc. Eur. Soc. Study Drug Toxicity 1969; 10: 94–100
   Google Scholar
• Volk B., Amelizad Z., Anagnostopoulos J., Knoth R., Oesch F. First evidence of cytochrome P-450 induction in the mouse brain by phenytoin. Neurosci. Lett. 1988; 84: 219–224
   PubMed Web of Science ®Google Scholar
• Marietta M. P., Vesell E. S., Hartmann R. D., Weisz J., Dvorchik B. H. Characterization of cytochrome P-450 dependent aminopy-rine N-demethylation in rat brain: Comparison with hepatic aminopy-rine N-demethylation. J. Pharmacol. Exp. Then 1979; 208: 271–279
   PubMed Web of Science ®Google Scholar
• Shiverick K. T., Notelovitz M. Mestranol-induced hypertension: Characterization of cytochrome P-450 dependent catechol estrogen formation in brain microsomes. Biochem. Pharmacol. 1983; 32: 101–106
   PubMed Web of Science ®Google Scholar
• Sasame H. A., Ames M. M., Nelson S. D. Cytochrome P-450 and NADPH cytochrome c reductase in rat brain: Formation of catechols and reactive catechol metabolites. Biochem. Biophys. Res. Commun. 1977; 78: 919–926
   PubMed Web of Science ®Google Scholar
• Cohn J. A., Alvares A. P., Kappas A. On the occurrence of cytochrome P-450 and aryl hydrocarbon hydroxylase activity in rat brain. JExp. Med. 1977; 145: 1607–1611
   Web of Science ®Google Scholar
• Walther B., Ghersi-Egea J. F., Minn A., Siest G. Subcellular distribution of cytochrome P-450 in the brain. Brain Res. 1986; 375: 338–344
   PubMed Web of Science ®Google Scholar
• Warner M., Kohler C., Hansson T., Gustafson J. -A. Regional distribution of cytochrome P-450 in the rat brain: Spectral quantitation and contribution of P-450b,e and P-450c,d. J. Neurochem. 1988; 50: 1057–1064
   PubMed Web of Science ®Google Scholar
• Paul S. M., Axelrod J., Diliberto E. J., Jr. Catechol estrogen-forming enzyme of brain: Demonstration of a cytochrome P-450 monooxygenase. Endocrinology 1977; 101: 1604–1610
   PubMed Web of Science ®Google Scholar
• Mesnil M., Testa B., Jenner P. Aryl hydrocarbon hydroxylase in rat brain microsomes. Biochem. Pharmacol. 1985; 34: 435–436
   Web of Science ®Google Scholar
• Srivastava S. P., Seth P. K. 7-Ethoxycoumarin 0-deethylase activity in rat brain microsomes. Biochem. Pharmacol. 1983; 32: 3657–3660
   PubMed Web of Science ®Google Scholar
• Ghersi-Egea J. F., Walther B., Perrin R., Minn A., Siest G. Inducibility of rat brain drug-metabolizing enzymes. Eur. J. Drug Metabol. Pharmacokin. 1987; 12: 263–265
   PubMed Web of Science ®Google Scholar
• Rouet P., Alexandrov K., Markovits P., Frayssinet C., Dansette P. M. Metabolism of benzo[a]pyrene by brain microsomes of fetal and adult rats and mice. Induction by 5,6-benzoflavone, comparison with liver and lung microsomal activities. Carcinogenesis 1981; 2: 919–926
   PubMed Web of Science ®Google Scholar
• Das M., Seth P. K., Mukhtar H. Characterization of microsomal aryl hydrocarbon hydroxylase of rat brain. J. Pharmacol. Exp. Then 1981; 216: 156–161
   PubMed Web of Science ®Google Scholar
• Das M., Seth P. K., Mukhtar H. NADH-dependent inducible aryl hydrocarbon hydroxylase activity in rat brain mitochondria. Drug Metab. Dispos. 1971; 9: 69–70
   Google Scholar
• Das M., Seth P. K., Dixit R., Mukhtar H. Aryl hydrocarbon hydroxylase of rat brain mitochondria: Properties of, and effect of inhibitors and inducers on, enzyme activity. Arch. Biochem. Bio-phys. 1982; 217: 205–215
   PubMed Web of Science ®Google Scholar
• Oesch F., Glatt H., Schmassmann H. The apparent ubiquity of epoxide hydratase in rat organs. Biochem. Pharmacol. 1977; 26: 603–607
   PubMed Web of Science ®Google Scholar
• Walther B., Ghersi-Egea J. -F., Jayyosi Z., Minn A, Siest G. Ethoxyresorufin O-deethylase activity in rat brain subcellular fractions. Neuroscience Lett. 1987; 76: 58–62
   PubMed Web of Science ®Google Scholar
• Kodeira H., Spector S. Transformation of thebaine to ori-pavine, codeine, and morphine by rat liver, kidney, and brain microsomes. Proc. Natl. Acad. Sci. USA 1988; 85: 1267–1271
   PubMed Web of Science ®Google Scholar
• Benuck M., Reith M. E. A., Shershen H., Wiener H. L., Lajtha A. Oxidative metabolism of cocaine: Comparison of brain and liver. Proc. Soc. Exp. Biol. Med. 1989; 190: 7–13
   PubMed Web of Science ®Google Scholar
• Watanabe K., Tanaka T., Yamamoto I., Yoshimura H. Brain microsomal oxidation of A8-and A9-tetrahydrocannabinol. Biochem. Biophys. Res. Commun. 1988; 157: 75–80
   PubMed Web of Science ®Google Scholar
• Christensen H. D., Freudenthal R. I., Gidlay J. T., Rosenfeld R., Boegli G., Testino L., Brine D. R., Pitt C. G., Wall M. E. Activity of A8-and A9-tetrahydrocannabinol and related compounds in the mouse. Science 1971; 172: 165–167
   PubMed Web of Science ®Google Scholar
• Yamamoto I., Narimatsu S., Watanabe K., Shimonishi T., Yoshimura H., Nagano T. Human liver microsomal oxidation of A8-tetrahydrocannabinol. Chem. Pharm. Bull. 1983; 31: 1784–1787
   PubMed Web of Science ®Google Scholar
• Quato M. K., Maines M. D. Regulation of heme and drug metabolism activities in the brain by manganese. Biochem. Biophys. Res. Commun. 1985; 128: 18–24
   PubMed Web of Science ®Google Scholar
• Chen Z. R., Irvine R. J., Bochner F., Somogyi A. A. Morphine formation from codeine in rat brain: A possible mechanism of codeine analgesia. Life Sci. 1990; 46: 1067–1074
   PubMed Web of Science ®Google Scholar
• Masana M., de Toranzo E. G. D., Castro J. A. Studies on ni-furtimox nitroreductase activity in liver and other rat tissues. Arch. Int. Pharmacodyn 1984; 270: 4–10
   PubMedGoogle Scholar
• Kochli H. W., Wermuth B., von Wartburg J. -P. Characterization of a mitochondrial NADH-dependent nitro reductase from rat brain. Biochim. Biophys. Acta 1980; 616: 133–142
   PubMed Web of Science ®Google Scholar
• Hook G. E. R., Haseman J. K., Lucier G. W. Induction and suppression of hepatic and extrahepatic foreign-compound metabolizing enzyme systems by 2,3,7,8-tetrachlorodibenzo-/?-dioxin. Chem.-Biol. Interact. 1975; 10: 199–214
   PubMed Web of Science ®Google Scholar
• White H. L., Wu J. C. Multiple binding sites of human brain monoamine oxidase as indicated by substrate competition. J. Neu-rochem 1975; 25: 21–26
   PubMed Web of Science ®Google Scholar
• Gabay S., Achee F. M., Mentes G. Some parameters affecting the activity of monoamine oxidase in purified bovine brain mitochondria. J. Neurochem. 1976; 27: 415–424
   PubMed Web of Science ®Google Scholar
• Schuur A., Ho B. T., Schoolar J. C. Human brain monoamine oxidase: One molecular entity–multiple binding sites. J. Pharm. Pharmacol. 1981; 33: 165–170
   PubMed Web of Science ®Google Scholar
• Sitaram B. R., Talomsin R., Blackman G. L., McLeod W. R. Study of metabolism of psychotomimetic indolealkylamines by rat tissue extracts using liquid chromatography. Biochem. Pharmacol. 1987; 36: 1503–1508
   PubMed Web of Science ®Google Scholar
• Barker S. A., Monti J. A., Christian S. T. Metabolism of the hallucinogen iV.iV-dimethyltryptamine in rat brain homogenates. Biochem. Pharmacol. 1980; 29: 1049–1057
   PubMed Web of Science ®Google Scholar
• Chemnitius J. M., Zech R. Carboxylesterases in primate brain: Characterization of multiple forms. Int. J. Biochem. 1983; 15: 1019–1025
   PubMedGoogle Scholar
• Hj Oring N., Svensmark O. Carboxylesterases of human brain extract. Purification and properties of a butyrylesterase. Biochim. Bio-phys. Acta 1977; 481: 500–514
   PubMed Web of Science ®Google Scholar
• Dabich D., Chakrapani B., Syner F. N. Purification and properties of esterases characteristic of adult rat brain. Biochem. J. 1968; 110: 713–718
   PubMed Web of Science ®Google Scholar
• Selfe S., Storm D. R. Deacetylation of forskolin catalyzed by bovine brain membranes. Biochem. Biophys. Res. Commun. 1985; 133: 52–59
   PubMed Web of Science ®Google Scholar
• Bhat S. V., Bajwa B. S., Dornauer M., de Souza N. J. Structures and stereochemistry of new labdane diterpenoids from Coleus forskohlii Briq. Tetrahedron Lett. 1977; 19: 1669–1672
   Google Scholar
• Way E. L., Young J. M., Kemp J. W. Metabolism of heroin and its pharmacologic implications. Bull. Narc 1965; 17: 25–33
   Google Scholar
• Maksay G., Kardos J., Simonyi M., Tegyey Zs., Otvos L. Specific binding of racemic oxazepam to rat brain synaptosomes. Arzne-imittelforsch.lDrug Res. 1981; 31: 979–981
   PubMed Web of Science ®Google Scholar
• Oomen A., George S. T., Balasubramanian A. S. Phenacetin iV-deacetylase and its nonidentity with the serotonin-sensitive aryl acylamidase of brain. Life Sci. 1980; 26: 2129–2136
   PubMed Web of Science ®Google Scholar
• Oomen A., Balasubramanian A. S. The association of serotonin-sensitive aryl acylamidase with acetylcholinesterase in the monkey brain. Eur. J. Biochem. 1979; 94: 135–143
   PubMedGoogle Scholar
• George S. T., Balasubramanian A. S. The identity of the serotonin-sensitive aryl acylamidase with acetylcholinesterase from human erythrocytes, sheep basal ganglia and electric eel. Eur J. Biochem. 1980; HI: 511–524
   Google Scholar
• Moore D. E., Hess G. P. Acetylcholinesterase-catalyzed hydrolysis of an amide. Biochemistry 1975; 14: 2386–2389
   PubMed Web of Science ®Google Scholar
• Hsu L. L., Halaris A. E., Freedman D. X. Rat brain aryl acylamidase: Further characterization of multiple forms. Int. J. Biochem. 1982; 14: 581–584
   PubMedGoogle Scholar
• Fujimoto D. Serotonin-sensitive aryl acylamidase in rat brain. Biochem. Biophys. Res. Commun. 1974; 61: 12–14
   Google Scholar
• Ramsay R. B., Smith K. R., Jr., Crafts D. C., Chung H. D., Fredericks M. Hydrolytic enzyme activities of the nervous system. Arch. Neurol. 1980; 37: 356–359
   PubMed Web of Science ®Google Scholar
• Alvares K., Balasubramanian A. S. Lysosomal and microsomal B-glucuronidase of monkey brain. Differential elution characteristics from Con A-sepharose and neutral sugar composition. Biochim. Bio-phys. Acta 1982; 708: 124–133
   PubMed Web of Science ®Google Scholar
• Stevens R. L., Fluharty A. L., Killgrove A. R., Kihara H. Ar-ylsulfatase of human tissue. Studies on a form of arylsulfatase B found predominantly in brain. Biochim. Biophys. Acta 1977; 481: 549–560
   PubMed Web of Science ®Google Scholar
• Mathew J., Balasubramanian A. S. ArySulphatase C and estrone sulphatase of sheep hypothalamus, preoptic area, and midbrain: Separation of hydrophobic interaction chromatography and evidence for differences in their lipid environment. J. Neurochem. 1982; 39: 1205–1209
   PubMed Web of Science ®Google Scholar
• Balasubramanian K. A., Bachhawat B. K. Purification, properties and glycoprotein nature of arylsulfatase A from sheep brain. Biochim. Biophys. Acta 1975; 403: 113–121
   PubMed Web of Science ®Google Scholar
• Iwamori M., Moser H. W., Kishimoto Y. Steroid sulfatase in brain: Comparison of sulfohydrolase activities for various steroid sulfates in normal and pathological brains, including the various forms of metachromatic leukodystrophy. J. Neurochem. 1976; 27: 1389–1395
   PubMed Web of Science ®Google Scholar
• Eto Y., Rampini S., Wiesmann U., Herschkovitz N. N. Enzy-mic studies of sulphatases in tissues of the normal human and in metachromatic leukodystrophy with multiple sulphatase deficiences: Arylsulphatases A, B, and C, cerebroside sulphatase, psychosine sulphatase and steroid sulphatases. J. Neurochem 1974; 23: 1161–1170
   PubMed Web of Science ®Google Scholar
• Lakshmi S., Balasubramanian A. S. The distribution of estrone sulphatase, dehydroepiandrosterone sulphatase, and arylsulphatase C in the primate (Macaca radiata) brain and pituitary. J. Neurochem. 1981; 37: 358–362
   PubMedGoogle Scholar
• Perumal A. S., Robins E. Regional and subcellular distribution of aryl-and steroid sulfatases in brain. Brain Res. 1973; 59: 349–358
   PubMed Web of Science ®Google Scholar
• Knapstein P., David A., Wu C. H., Archer D. F., Flickinger G. L., Touchstone J. C. Metabolism of free and sulfoconjugated DHEA in brain tissue in vivo and in vitro. Steroids 1968; 11: 885–896
   PubMed Web of Science ®Google Scholar
• Hobkirk R. Steroid sulfotransferases and steroid sulfatases: Characteristics and biological roles. Can. J. Biochem. Cell Biol. 1985; 63: 1127–1144
   PubMedGoogle Scholar
• Cash C. D., Maitre M., Rumigny J. F., Weissman-Nanopoulos D., Mandel P. Succinate semialdehyde reductases and their product: 4-hydroxybutyrate. Enzymology ofCarbonyl Metabolism: Aldehyde Dehydrogenase and Aldo/Keto Reductase, H. Weiner, B. Wermuth. Alan Liss, New York 1982; 379–395
   Google Scholar
• Wermuth B., Burgisser H., Bohren K., von Wartburg J. P. Purification and characterization of human brain aldose reductase. Eur. J. Biochem. 1982; 127: 279–284
   PubMedGoogle Scholar
• Boghosian R. A., McGuinness E. T. Affinity purification and properties of porcine brain aldose reductase. Biochim. Biophys. Acta 1979; 567: 278–286
   PubMed Web of Science ®Google Scholar
• Wermuth B. Purification and properties of an NADPH-dependent carbonyl reductase from human brain. J. Biol. Chem. 1981; 256: 1206–1213
   PubMed Web of Science ®Google Scholar
• O'Brien M. M., Schofield R J. Polyol-pathway enzymes of human brain. Partial purification and properties of aldose reductase and hexonate dehydrogenase. Biochem. J. 1980; 187: 21–30
   PubMed Web of Science ®Google Scholar
• Hoffman P. L., Wermuth B., von Wartburg J. -P. Multiple aldehyde reductases of human brain. Adv. Exp. Med. Biol. 1980; 132: 749–759
   PubMedGoogle Scholar
• Ris M. M., von Wartburg J. -P. Heterogeneity of NADPH-dependent aldehyde reductase from human and rat brain. Eur. J. Biochem. 1973; 37: 69–77
   PubMedGoogle Scholar
• Ryle C. M., Tipton K. E. Subcellular localization of aldehyde reductase activities in ox brain. Biochem. J. 1981; 197: 715–720
   PubMed Web of Science ®Google Scholar
• Rivett A. J., Smith I. L., Tipton K. F. The enzymes catalysing succinic semialdehyde reduction in rat brain. Biochem. Pharmacol. 1981; 30: 741–747
   PubMed Web of Science ®Google Scholar
• Tabakoff B., Anderson R., Alivisatos S. G. A. Enzymatic reduction of “biogenic” aldehydes in brain. Mol. Pharmacol. 1973; 9: 428–437
   PubMed Web of Science ®Google Scholar
• Wermuth B. Human carbonyl reductases. Enzymology of Carbonyl Metabolism: Aldehyde Dehydrogenase and Aldo/Keto Reductase, H. Weiner, B. Wermuth. Alan Liss, New York 1982; 261–274
   Google Scholar
• Bohren K. M., von Wartburg J. -P., Wermuth B. Kinetics of carbonyl reductase from human brain. Biochem. J. 1987; 244: 165–171
   PubMed Web of Science ®Google Scholar
• Hoffman P. L., Wermuth B., von Wartburg J. P. Human brain aldehyde reductases: Relationship to succinic semialdehyde reductase and aldose reductase. J. Neurochem. 1980; 35: 354–366
   PubMed Web of Science ®Google Scholar
• Enzyme Nomenclature, Recommendations (1984)) of the Committee of the International Union of Biochemists. Academic Press, New York 1984
   Google Scholar
• Turner A. J. Aldehyde reductases: Enzymes in search of a function. Enzymology of Carbonyl Metabolism: Aldehyde Dehydrogenase and AldolKeto Reductase, H. Weiner, B. Wermuth. Alan Liss, New York 1982; 183–195
   Google Scholar
• Monder C., Bradlow H. L. Cortoic acids: Explorations at the frontier of corticosteroid metabolism. Recent Progr. Hormone Res. 1980; 36: 345–400
   PubMedGoogle Scholar
• Lipman V., Monder C. Purification and properties of an NADPH-dependent 21-oxo-20-hydroxysteroid reductase (170-aldol reducatase) from sheep liver. JBiol. Chem. 1978; 253: 2126–2131
   PubMed Web of Science ®Google Scholar
• Turner A. J., Tipton K. F. The characterization of two reduced nicotinamide-adenine dinucleotide phosphate-linked aldehyde reductases from pig brain. Biochem. J. 1972; 130: 765–772
   PubMed Web of Science ®Google Scholar
• Matsuda Y. M., Hoshino H. Conversion in vivo of succinic semi-aldehyde to 4-hydroxybutyrate in the mouse. Jikeikai Med. J. 1976; 23: 189, as cited by Cash et al. [412]
   Google Scholar
• Turner A. J., Flynn T. G. The nomenclature of aldehyde reductases. Enzymology of Carbonyl Metabolism: Aldehyde Dehydrogenase and AldolKeto Reductase, H. Weiner, B. Wermuth. Alan Liss, New York 1982; 401–402
   Google Scholar
• Flynn T. G. Aldehyde reductases: Monomeric NADPH-dependent oxidoreductases with multifunctional potential. Biochem. Pharmacol. 1982; 31: 2705–2712
   PubMed Web of Science ®Google Scholar
• Agarwal D. P, Hafer G., Harada S., Goedde H. W. Studies on aldehyde dehydrogenase and aldehyde reductase in human brain. Enzymology of Carbonyl Metabolism: Aldehyde Dehydrogenase and AldolKeto Reductase, H. Weiner, B. Wermuth. Alan Liss, New York 1982; 319–327
   Google Scholar
• Harada S., Agarwal D. P., Goedde H. W. Human aldehyde dehydrogenase: 3,4-dihydroxyphenylaldehyde metabolizing enzymes. Enzymology of Carbonyl Metabolism: Aldehyde Dehydrogenase and AldolKeto Reductase, H. Weiner, B. Wermuth. Alan Liss, New York 1982; 147–153
   Google Scholar
• Aitio A. UDP glucuronosyltransferase activity in various rat tissues. Int. J. Biochem. 1974; 5: 325–330
   Google Scholar
• Ghersi-Egea J. F., Walther B., Decolin D., Minn A., Siest G. The activity of 1-naphthol-UDP-glucuronosyltransferase in the brain. Neuropharmacology 1987; 26: 367–372
   PubMed Web of Science ®Google Scholar
• Shigezane J., Oguri K., Mishima M., Yoshimura H. UDP-glu-curonyltransferases in mice brain and the inducibility. J. Pharmaco-Dyn. 1982; 5: S–61
   Google Scholar
• Ghersi-Egea J. F., Tayarani Y., Lefauconnier J. M., Minn A. Enzymatic protection of the brain: Role of 1-naphthol UDP-glucu-ronosyltransferase from cerebral tissue and cerebral microvessels. Cell. Molec. Aspects of Glucuronidation, G. Siest, J. Magdalou, B. Burchell. Colloque INSERM/John Libbey Eurotext Ltd. 1988; 173: 169–175
   Google Scholar
• Wahlstrom A., Hammar L., Lundin L. -G., Rane A. Morphine metabolism in mouse brain. Natl. Inst. Drug Abuse Res. Monogr. Sen 1986; 75: 603–606
   PubMedGoogle Scholar
• Renskers K. J., Feor K. D., Roth J. A. Sulfation of dopamine and other biogenic amines by human phenol sulfotransferase. J. Neu-rochem. 1980; 34: 1362–1368
   PubMed Web of Science ®Google Scholar
• Giorgi O., Meek J. L. Sulfation of peptides and simple phenols by rat brain phenolsulfotransferase. Inhibition by dichloronitrophe-nol. Biochem. Pharmacol. 1985; 34: 45–49
   PubMed Web of Science ®Google Scholar
• Young W. F., Jr., Laws E. R., Jr., Scarbrough F. W., Weinshilboum R. M. Human phenol sulfotransferase: Correlation of brain and platelet activities. JNeurochem. 1985; 44: 1131–1137
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. M. Phenol sulfotransferase in humans: Properties, regulation, and function. Fed. Proc 1986; 45: 2223–2228
   PubMedGoogle Scholar
• Wong K. P. The biosynthesis of 3-methoxy-4-hydroxyphenylgIycol sulphate by liver and brain. J. Neurochem. 1975; 24: 1059–1063
   PubMed Web of Science ®Google Scholar
• Pennings E. J. M., Vrielink R., van Kempen G. M. J. Kinetics and mechanism of the rat brain phenol sulphotransferase reaction. Biochem. J. 1978; 173: 299–307
   PubMed Web of Science ®Google Scholar
• Pennings E. J. M., Vrielink R., Wolters W. L., van Kempen G. M. J. Inhibition of rat brain phenol sulphotransferase in vitro by noradrenaline and dopamine metabolites. J. Neurochem. 1976; 27: 915–920
   PubMed Web of Science ®Google Scholar
• Rein G., Glover V., Sandler M. Characterization of human brain phenolsulfotransferase. J. Neurochem. 1984; 42: 80–85
   PubMed Web of Science ®Google Scholar
• Rein G., Glover V., Sandler M. Multiple forms of phenolsul-photransferase in human tissues. Selective inhibition by dichloroni-trophenol. Biochem. Pharmacol. 1982; 31: 1893–1897
   PubMed Web of Science ®Google Scholar
• Foldes A., Meek J. L. Rat brain phenolsulfotransferase–partial purification and some properties. Biochim. Biophys. Acta 1973; 327: 365–374
   PubMed Web of Science ®Google Scholar
• Young W. F., Jr., Okazaki H., Laws E. R., Jr., Weinshilboum R. M. Human brain phenol sulfotransferase: Biochemical properties and regional localization. J. Neurochem. 1984; 43: 706–715
   PubMed Web of Science ®Google Scholar
• Jenner W. N., Rose F. A. Studies on the sulphation of 3,4-dihydroxyphenylethylamine (dopamine) and related compounds by rat tissues. Biochem. J. 1973; 135: 109–114
   PubMed Web of Science ®Google Scholar
• Karoum F., Moyer-Schwing J., Potkin S. G., Wyatt R. J. Presence of free, sulfate and glucuronide conjugated 3-methoxy-4-hydroxyphenylglycol in human brain, cerebrospinal fluid and plasma. Brain Res. 1977; 125: 333–339
   PubMed Web of Science ®Google Scholar
• Schanberg S. M., Schildkraut J. J., Breese G. R., Kopin I. J. Metabolism of normetanephrine-3H in rat brain–identification of conjugated 3-methoxy-4-hydroxyphenylglycol as the major metabolite. Biochem. Pharmacol. 1968; 17: 247–254
   PubMed Web of Science ®Google Scholar
• Tyce G. M., Messick J. M., Yaksh T. L., Byer D. E. V., Danielson D. R., Rorie D. K. Amine sulfate formation in the central nervous system. Fed. Proc 1986; 45: 2247–2253
   PubMedGoogle Scholar
• Borchardt R. T., Cheng C. F. Purification and characterization of rat heart and brain catechol methyltransferase. Biochim. Bio-phys. Acta 1978; 522: 49–62
   PubMed Web of Science ®Google Scholar
• White H. L., Wu J. C. Properties of catechol 0-methyl-transferases from brain and liver of rat and human. Biochem. J. 1975; 145: 135–143
   PubMed Web of Science ®Google Scholar
• Boppana V. K., Dolce K. M., Cyronak M. J., Ziemniak J. A. Simplified procedures for the determination of fenoldopam and its metabolites in human plasma by high-performance liquid chromatography with electrochemical detection: Comparison of manual and robotic preparation methods. J. Chromatogr. 1989; 487: 385–399
   PubMed Web of Science ®Google Scholar
• Burba J. V., Becking G. C. Effect of the antioxidant nordihy-droguaiaretic acid on the in vitro activity of catechol-O-methyl-transferase. Arch. Int. Pharmacodyn. 1969; 180: 323–330
   PubMedGoogle Scholar
• Gordonsmith R. H., Raxworthy M. J., Gulliver P. A. Substrate stereospecificity and selectivity of catechol-0-methyltransferase for dopa, dopa derivatives and a-substituted catecholamines. Biochem. Pharmacol. 1982; 31: 433–437
   PubMed Web of Science ®Google Scholar
• Hagan R. M., Raxworthy M. J., Gulliver P. A. Benserazide and carbidopa as substrates of catechol-O-methyltransferase: New mechanism of action in Parkinson's disease. Biochem. Pharmacol. 1980; 29: 3123–3126
   PubMed Web of Science ®Google Scholar
• Hsu L. L., Geyer M. A., Mandell A. J. Extrapineal amine N-acetylation in rat brain. Biochem. Pharmacol. 1976; 25: 815–819
   PubMed Web of Science ®Google Scholar
• Yang H. -Y.T., Neff N. H. Brain N-acetyltransferase: Substrate specificity, distribution and comparison with enzyme activity from other tissues. Neuropharmacology 1976; 15: 561–564
   PubMed Web of Science ®Google Scholar
• Voisin P., Namboodiri M. A. A., Klein D. C. Arylamine N-acetyltransferase and arylalkylamine N-acetyltransferase in the mammalian pineal gland. J. Biol. Chem. 1984; 259: 10913–10918
   PubMed Web of Science ®Google Scholar
• Paul S. M., Hus L. L., Mandell A. J. Extrapineal N-acetyltransferase activity in rat brain. Life Sci. 1975; 15: 2135–2143
   Web of Science ®Google Scholar
• Chasseaud L. F. The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv. Cancer Res. 1979; 29: 175–274
   PubMedGoogle Scholar
• Das M., Mukhtar H., Seth P. K. Effect of acrylamide on brain and hepatic mixed-function oxidases and gluthathione 5-transferase in rats. Toxicol. Appl. Pharmacol. 1982; 66: 420–426
   PubMed Web of Science ®Google Scholar
• Di Ilio C., Polidoro G., Arduini A., Federici G. Glutathione 5-transferase activity from guinea-pig brain: A comparison with hepatic multiple forms. Gen. Pharmacol. 1982; 13: 485–490
   PubMedGoogle Scholar
• Kubota T., Miyaura S., Isono H. Rat brain glutathione 5-transferases. Chem. Pharm. Bull. 1985; 33: 5399–5403
   PubMed Web of Science ®Google Scholar
• Dierickx P. J. Soluble glutathione 5-transferase isoenzymes in rat brain. Toxicology Lett. 1983; 18: 121–125
   PubMed Web of Science ®Google Scholar
• Asaoka K., Takahashi K. Purification and properties of porcine brain glutathione 5-transferases. J. Biochem. 1983; 94: 1191–1199
   PubMed Web of Science ®Google Scholar
• Young P. R., Briedis A. V. Purification and kinetic mechanism of the major glutathione 5-transferase from bovine brain. Biochem. J. 1989; 257: 541–548
   PubMed Web of Science ®Google Scholar
• Ogorochi T., Ujihara M., Narumiya S. Purification and properties of prostaglandin H-E isomerase from the cytosol of human brain: Identification as anionic forms of glutathione 5-transferase. J. Neuro-chem. 1987; 48: 900–909
   PubMed Web of Science ®Google Scholar
• Das M., Mukhtar H., Seth P. K. Aryl hydrocarbon hydroxylase and glutathione-5-transferase activities in discrete regions of rat brain. Toxicol. Lett. 1982; 13: 125–128
   PubMed Web of Science ®Google Scholar
• Das M., Dixit R., Seth P. K., Mukhtar H. Glutathione 5-transferase activity in the brain: Species, sex, regional and age differences. J. Neurochem. 1981; 36: 1439–1442
   PubMed Web of Science ®Google Scholar
• Dixit R., Mukhtar H., Seth P. K., Krishna Murti C. R. Conjugation of acrylamide with glutathione catalysed by glutathiones-transferase of rat liver and brain. Biochem. Pharmacol. 1981; 30: 1739–1744
   PubMed Web of Science ®Google Scholar
• Dixit R., Seth P. K., Mukhtar H. Brain glutathiones-transferase catalyzed conjugation of acrylamide: A novel mechanism for detoxification of neurotoxin. Biochem. Int. 1980; 1: 547–552
   Google Scholar
• Abramovitz M., Homma H., Ishigaki S., Tansey F., Cammer W., Listowsky I. Characterization and localization of glutathione-5-transferases in rat brain and binding of hormones, neurotransmitters, and drugs. J. Neurochem. 1988; 50: 50–57
   PubMed Web of Science ®Google Scholar
• Olsson M., Guthenberg C., Mannervik B. Glutathione transferase in human brain. Extrahepatic Drug Metabolism and Chemical Carcinogenesis, J. Rydstrom, J. Montelius, M. Bengtsson. Elsevier Science Publishers. 1983; 191–192
   Google Scholar
• Hopewell J. W., Wright E. A. The importance of implantation site in cerebral carcinogenesis. Cancer Res. 1969; 29: 1927–1931
   PubMed Web of Science ®Google Scholar
• Markovits P., Le S. Vy, Nocentini S., Mazabraud A., Velizarov A., Sabharwal P. S., Benda P. Transformation maligne in vitro de cellules de cerveau foetal de hamster par le benzo(a)pyrene. Compt. Rend. Acad. Sci. Paris 1976; 282: 2015–2020
   Google Scholar
• Rice J. M., Joshi S. R., Shenefelt R. E., Wenk M. L. Transplacental carcinogenic activity of 7,12-dimethylbenz[a]anthracene. Carcinogenesis 1978; 3: 413–422
   Google Scholar
• Juchau M. R., Di Giovanni J., Namkung M. J., Jones A. H. A comparison of the capacity of fetal and adult liver, lung, and brain to convert polycyclic aromatic hydrocarbons to mutagenic and cytotoxic metabolites in mice and rats. Toxicol. Appl. Pharmacol. 1979; 49: 171–178
   PubMed Web of Science ®Google Scholar
• Langston J. W., Ballard P., Tetrud J. W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–980
   PubMed Web of Science ®Google Scholar
• Forno L. S. Pathology of Parkinson's disease. Movement Disorders, C. D. Marsden, S. Fahn. Butterworth Scientific, London 1982; 25–40
   Google Scholar
• Burns R. S., Chieuh C. C., Markey S. P., Ebert M. H., Jaco-bowitz D. M., Kopin I. J. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 1983; 80: 4546–4550
   PubMed Web of Science ®Google Scholar
• Davis G. C., Williams A. C., Markey S. P., Ebert M. H., Caine E. D., Reichert C. M., Kopin I. J. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979; 1: 249–254
   PubMed Web of Science ®Google Scholar
• Weissman J., Trevor A., Chiba K., Peterson L. A., Caldera P., Castagnoli N., Jr. Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine by liver homogenate fractions. J. Med. Chem. 1985; 28: 997–1001
   PubMed Web of Science ®Google Scholar
• DiMonte D., Shinka T., Sandy M. S., Castagnoli N., Jr., Smith M. T. Quantitative analysis of l-methyl-4-phenyl-l,2,3,6-tetrahy-dropyridine metabolism in isolated rat hepatocytes. Drug. Metab. Dispos. 1988; 16: 250–255
   PubMed Web of Science ®Google Scholar
• Riachi N. J., La Manna J. C., Harik S. I. Entry of 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine into the rat brain. J. Pharmacol. Exp. Then 1989; 249: 744–748
   PubMed Web of Science ®Google Scholar
• Markey S. P., Johannessen J. N., Chiueh C. C., Burns R. S., Herkenham M. A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984; 311: 464–467
   PubMed Web of Science ®Google Scholar
• Heikkila R. E., Manzino L., Cabbat F. S., Duvoisin R. C. Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984; 311: 467–469
   PubMed Web of Science ®Google Scholar
• Shinka E. WuT., Caldera-Munoz P., Yoshizumi H., Trevor A., Castagnoli N., Jr. Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+. Chem. Res. Toxicol. 1988; 1: 186–194
   PubMed Web of Science ®Google Scholar
• Heikkila R. E., Kindt M. V., Sonsalla P. K., Giovanni A., Youngster S. K., McKeown K. A., Singer T. P. Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 1988; 85: 6172–6176
   PubMed Web of Science ®Google Scholar
• Chiba K., Trevor A., Castagnoli N., Jr. Metabolism of the neurotoxic amine, MPTP, by brain monoamine oxidase. Biochem. Bio-phys. Res. Commun. 1984; 120: 574–578
   PubMed Web of Science ®Google Scholar
• Heikkila R., Duvoisin R. C., Finberg J. P. M., You-dim M. B. H. Prevention of MPTP-induced neurotoxicity by AGN-1I33 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 1985; 116: 313–317
   PubMed Web of Science ®Google Scholar
• Youngster S. K., Sonsalla P. K., Sieber B. -A., Heikkila R. E. Structure-activity study of the mechanism of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs. J. Pharmacol. Exp. Then 1989; 249: 820–828
   PubMed Web of Science ®Google Scholar
• Niwa T., Yoshizumi H., Tatematsu A., Matsuura S., Nagatsu T. Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in food. J. Chromatogn 1989; 493: 347–352
   PubMed Web of Science ®Google Scholar
• Niwa T., Takeda N., Sasaoka T., Kaneda N., Hashizume Y., Yoshizumi H., Tatematsu A., Nagatsu T. Detection of tetrahydroisoquinoline in parkinsonian brain as an endogenous amine by use of gas chromatography-mass spectrometry. J. Chromatogn 1989; 491: 397–403
   PubMed Web of Science ®Google Scholar
• Niwa T., Takeda N., Kaneda N., Hashizume Y., Nagatsu T. Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. Biochem. Biophys. Res. Commun. 1987; 144: 1084–1089
   PubMed Web of Science ®Google Scholar
• Naoi M., Matsuura S., Takahashi T., Nagatsu T. AN-methyltransferase in human brain catalyzes W-methylation of 1,2,3,4,-tetrahydroisoquinoline into N-methyl-1,2,3,4-tetrahydroiso-quinoline, a precursor of a dopaminergic neurotoxin, /V-methyliso-quinolinium ion. Biochem. Biophys. Res. Commun. 1989; 161: 1213–1219
   PubMed Web of Science ®Google Scholar
• Naoi M., Matsuura S., Parvez H., Takahashi T., Hirata Y., Mi-nami M., Nagatsu T. Oxidation of N-methyl-1,2,3,4,-tetrahydro-isoquinoline into the, /V-methyl-isoquinolinium ion by monoamine oxidase. J. Neurochem. 1989; 52: 653–655
   PubMed Web of Science ®Google Scholar
• Nagatsu T., Yoshida M. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigros-triatal regions. Neurosci. Lett. 1988; 87: 178–182
   PubMed Web of Science ®Google Scholar
• Buege J. A., Aust S. D. Microsomal lipid peroxidation. Meth. Enzymol. 1978; 52: 302–310
   PubMedGoogle Scholar
• Sugimoto E., Takahashi N., Kitagawa Y., Chiba H. Intracellular localization and characterization of beef liver aldehyde dehydrogenase isozymes. Agric. Biol., Chem. 1976; 40: 2063–2070
   Web of Science ®Google Scholar
• Bhuyan K. C., Bhuyan D. K., Podos S. M. Evidence of increased lipid peroxidation in cataracts. 1RCS Medical Sci.: Biochem.; Clin. Biochem. 1981; 9: 126–127
   Google Scholar
• Benedetti A., Comporti M., Esterbauer H. Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochim. Biophys. Acta 1980; 620: 281–296
   PubMed Web of Science ®Google Scholar
• Susilo R., Damm H., Rommelspacher H. Formation of a new biogenic aldehyde adduct by incubation of tryptamine with rat brain tissue. J. Neurochem. 1988; 50: 1817–1824
   PubMed Web of Science ®Google Scholar
• Nilsson G. E., Tottmar O. Biogenic aldehydes in brain: On their preparation and reactions with rat brain tissue. J. Neurochem. 1987; 48: 1566–1572
   PubMed Web of Science ®Google Scholar
• Case G. L., Benevenga N. J. Significance of formate as an intermediate in the oxidation of the methionine, 5-methyl-L-cysteine and sarcosine methyl carbons to C02 in the rat. J. Nutr. 1977; 107: 1665–1676
   PubMed Web of Science ®Google Scholar
• Cochin J., Axelrod J. Biochemical and pharmacological changes in the rat following chronic administration of morphine, nalorphine and normorphine. J. Biol. Chem. 1959; 125: 105–110
   Google Scholar
• Uotila L., Koivusalo M. Formaldehyde dehydrogenase. Meth. Enzymol. 1981; 77: 314–320
   PubMedGoogle Scholar
• Cohen G., Collins M. Alkaloids from catecholamines in adrenal tissue: Possible role in alcoholism. Science 1970; 167: 1749–1751
   PubMed Web of Science ®Google Scholar
• Tuma D. J., Newman M. R., Donohue T. M., Jr., Sorrel M. F. Covalent binding of acetaldehyde to proteins: Participation of lysine residues. Alcoholism 1987; 11: 579–584
   Google Scholar
• Israel Y. Covalent binding of acetaldehyde to liver tubulin: A step in the right direction. Hepatology 1989; 9: 161–162
   PubMed Web of Science ®Google Scholar
• Jennet R. B., Sorrell M. F., Saffari-Fard A, Ockner J. L., Tuma D. J. Preferential covalent binding of acetaldehyde to the a-chain of purified rat liver tubulin. Hepatology 1989; 9: 57–62
   PubMed Web of Science ®Google Scholar
• Stevens V. J., Fantl W. J., Newman C. B. Acetaldehyde adducts with hemoglobin. J. Clin. Invest. 1981; 67: 361–369
   PubMed Web of Science ®Google Scholar
• Donohue T. M., Jr., Tuma D. J., Sorrell M. F. Acetaldehyde adducts with proteins: Binding of [14C]acetaldehyde to serum albumin. Arch. Biochem. Biophys. 1983; 220: 239–246
   PubMed Web of Science ®Google Scholar
• Jennett R. B., Saffari-Fard A., Sorrell M. F., Smith S. L., Tuma D. J. Increased covalent binding of acetaldehyde to calmodulin in the presence of calcium. Life Sci. 1989; 45: 1451–1466
   PubMedGoogle Scholar
• Smith S. L., Jennett R. B., Sorrell M. F., Tuma D. J. Acetaldehyde substoichiometrically inhibits bovine neurotubulin polymerization. J. Clin. Invest. 1989; 84: 337–341
   PubMed Web of Science ®Google Scholar
• Blaner W. S., Churchich J. Succinic semialdehyde dehydrogenase. Reactivity of lysyl residues. J. Biol. Chem. 1979; 254: 1794–1798
   PubMed Web of Science ®Google Scholar
• Frankel-Conrat H., Singer B. Nucleoside adducts are formed by cooperative reaction of acetaldehyde and alcohols: Possible mechanism for the role of ethanol in carcinogenesis. Proc. Natl. Acad. Sci. USA 1988; 85: 3758–3761
   PubMed Web of Science ®Google Scholar
• Schatzkin A., Jones D. Y., Hoover R. N., Taylor P. R., Brinton L. A., Ziegler R. G., Harvey E. B., Carter C. L., Licitra L. M., Dufour M. C., Larson D. B. Alcohol consumption and breast cancer in the epidemiologic follow-up study of the first national health and nutrition examination survey. N. Engl. J. Med. 1987; 316: 1169–1173
   PubMed Web of Science ®Google Scholar
• Willett W. C., Stampfer M. J., Colditz G. A., Rosner B. A., Hennekens C. H., Speizer F. E. Moderate alcohol consumption and the risk of breast cancer. N. Engl. J. Med. 1987; 316: 1174–1180
   PubMed Web of Science ®Google Scholar
• Murphy S. D. Casarett and Doull's Toxicology third ed., C. D. Klaassen, M. O. Amdur, J. Doull. Macmillan, New York 1986; 519–581
   Google Scholar
• Abou-Donia M. B. Organophosphorus ester-induced delayed neurotoxicity. Ann. Rev. Pharmacol. Toxicol. 1981; 21: 511–548
   PubMed Web of Science ®Google Scholar
• Mackness M. I. A-esterases: Enzymes looking for a role?. Biochem. Pharmacol. 1989; 38: 385–390
   PubMed Web of Science ®Google Scholar
• Johnson M. K. Improved assay of neurotoxic esterase for screening organophosphates for delayed neurotoxicity potential. Arch. Toxicol. 1977; 37: 113–115
   PubMed Web of Science ®Google Scholar
• Padilla S., Veronesi B. The relationship between neurological damage and neurotoxic esterase inhibition in rats acutely exposed to tri-ortho-cresyl phosphate. Toxicol. Appl. Pharmacol. 1985; 78: 78–87
   PubMed Web of Science ®Google Scholar
• Dudek B. R., Richardson R. J. Evidence for the existence of neurotoxic esterase in neural and lymphatic tissue of the adult hen. Biochem. Pharmacol. 1982; 31: 1117–1121
   PubMed Web of Science ®Google Scholar
• Mackness M. L., Thompson H. M., Hardy A. R., Walker C. H. Distinction between “A” esterases and arylesterases. Biochem. J. 1987; 245: 293–296
   PubMed Web of Science ®Google Scholar
• Johnson M. K. Organophosphates and delayed neuropathy–is NTE alive and well?. Toxicol. Appl. Pharmacol. 1990; 102: 385–399
   PubMed Web of Science ®Google Scholar
• Moretto A., Lotti M. Organ distribution and delayed neuropathy target esterase in man. Biochem. Pharmacol. 1988; 37: 3041–3043
   PubMed Web of Science ®Google Scholar
• Johnson M. K. Initiation of organophosphate neurotoxicity. Toxicol. Appl. Pharmacol. 1981; 61: 480–481
   PubMed Web of Science ®Google Scholar
• Lotti M., Johnson M. K. Neurotoxic esterase in human nervous tissue. J Neurochem. 1980; 34: 747–749
   PubMed Web of Science ®Google Scholar
• Pope C. N., Padilla S. S. Chromatographic characterization of neurotoxic esterase. Biochem. Pharmacol. 1989; 38: 181–188
   PubMed Web of Science ®Google Scholar
• Yu P. H., Boulton A. A. Regional oxidation of tyramine isomers in rat brain. J. Neurochem. 1980; 35: 255–257
   PubMed Web of Science ®Google Scholar
• Goldberg R., Tipton K. F. The distribution of catechol-O-methyltransferase in pig liver and brain. Biochem. Pharmacol. 1978; 27: 2623–2629
   PubMed Web of Science ®Google Scholar
• Hiemke C., Ghraf R. Distribution and properties of thiol S-methyltransferase in rat brain. J. Neurochem. 1983; 40: 592–594
   PubMed Web of Science ®Google Scholar
• Loscher W., Frey H. -H. Transport of GABA at the blood-CSF interface. J. Neurochem. 1982; 38: 1072–1079
   PubMed Web of Science ®Google Scholar
• Snodgrass S. R., Lorenzo A. V. Transport of GABA from the perfused ventricular system of the cat. J. Neurochem. 1973; 20: 761–769
   PubMed Web of Science ®Google Scholar
• Coceani F. Prostaglandins and the central nervous system. Arch. Intern. Med. 1974; 133: 119–129
   PubMed Web of Science ®Google Scholar
• Nakano J., Prancan A. V., Moore S. E. Metabolism of prostaglandin E, in the cerebral cortex and cerebellum of the dog and rat. Brain Res. 1972; 39: 545–548
   PubMed Web of Science ®Google Scholar
• Wolfe L. S., Rostworowski K., Pappus H. M. The endogenous biosynthesis of prostaglandins by brain tissue in vitro. Can. J. Bio-chem. 1976; 54: 629–640
   Web of Science ®Google Scholar
• Pace-Asciak C. R., Rangaraj G. Prostaglandin biosynthesis and catabolism in the developing fetal sheep brain. J. Biol. Chem. 1976; 251: 3381–3385
   PubMed Web of Science ®Google Scholar
• Abdel-Halim M. S., Anggard E. Regional and species differences in endogenous prostaglandin biosynthesis by brain homoge-nates. Prostaglandins 1979; 17: 411–418
   PubMedGoogle Scholar
• Dixon R. L., Owens E. S., Rail D. P. Evidence of active transport of benzyl-l4C-penicillin from cerebrospinal fluid to blood. JPharm. Sci. 1969; 58: 1106–1109
   PubMed Web of Science ®Google Scholar
• Dacey R. G., Sande M. A. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob. Ag. Chemother. 1974; 6: 437–441
   PubMed Web of Science ®Google Scholar
• Cutler R. W. P., Lorenzo A. V. Transport of 1-aminocyclo-pentane-carboxylic acid from feline cerebrospinal fluid. Science 1968; 161: 1363–1364
   PubMedGoogle Scholar
• Asghar K., Way E. L. Active removal of morphine from the cerebral ventricles. J. Pharmacol. Exp. Then 1970; 175: 75–83
   PubMed Web of Science ®Google Scholar
• Spector R., Lorenzo A. V. The transport and metabolism of salicylate in the central nervous system: In vivo studies. J. Pharmacol. Exp. Ther. 1973; 185: 276–286
   PubMed Web of Science ®Google Scholar
• Oldendorf W. H. Carrier-mediated blood-brain barrier transport of short-chain monocarboxylic organic acids. Am. J. Physiol. 1973; 224: 1450–1453
   PubMed Web of Science ®Google Scholar
• Conn A. R., Fell D. I., Steele R. D. Characterization of ot-keto acid transport across blood-brain barrier in rats. Am. J. Physiol. 1983; 245: E253–E260
   PubMed Web of Science ®Google Scholar
• Steele R. D. Blood-brain barrier transport of the a-keto acid analogs of amino acids. Fed. Proc 1986; 45: 2060–2064
   PubMedGoogle Scholar
• Huang J. T. Accumulation of peptide tyr-D-ala-gly by choroid plexus during ventriculocisternal perfusion of rat brain. Neurochem. Res. 1982; 7: 1541–1548
   Web of Science ®Google Scholar
• Lanman R. C., Schanker L. S. Transport out of the cranial cerebrospinal fluid spaces of the rabbit. JPharmacol. Exp. Ther. 1980; 215: 563–568
   PubMed Web of Science ®Google Scholar
• Lorenzo A. V. Factors governing the composition of the cerebrospinal fluid. Exp. Eye Res. 1977; 205–228, Suppl.
   PubMed Web of Science ®Google Scholar
• Bradbury M. W. B. The structure and function of the blood-brain barrier. Fed. Proc 1984; 43: 186–190
   PubMedGoogle Scholar
• Spector R., Sivesind C., Kinzenbaw D. Pantothenic acid transport through the blood-brain barrier. J. Neurochem. 1986; 47: 966–971
   PubMed Web of Science ®Google Scholar
• Pardridge W. M., Mietus L. J. Transport of steroid hormones through the rat blood-brain barrier. J. Clin. Invest. 1979; 64: 145–154
   PubMed Web of Science ®Google Scholar
• Pardridge W. M. Carrier-mediated transport of thyroid hormones through the rat blood-brain barrier: Primary role of albumin-bound hormone. Endocrinology 1979; 105: 605–612
   PubMed Web of Science ®Google Scholar
• Terasaki T., Pardridge W. M. Stereospecificity of triiodothyronine transport into brain, liver, and salivary gland: Role of carrier-and plasma protein-mediated transport. Endocrinology 1987; 121: 1185–1191
   PubMed Web of Science ®Google Scholar
• Bowman P. D., Betz A. L., Goldstein G. W. Primary culture of microvascular endothelial cells from bovine retina: Selective growth using fibronectin coated substrate and plasma derived serum. In Vitro 1982; 18: 626–632
   PubMedGoogle Scholar
• Dorovini-Zis K., Bowman P. D., Betz A. L., Goldstein G. W. Formation of a barrier by brain microvessel endothelial cells in culture. Fed. Proc. 1987; 46: 2521–2522
   PubMedGoogle Scholar
• Kalaria R. N., Harik S. I. Blood-brain barrier monoamine oxidase: Enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including human. J. Neurochem. 1987; 49: 856–864
   PubMed Web of Science ®Google Scholar
• Savion N., Farzame N. Characterization of the Na,K-ATPase pump in cultured bovine corneal endothelial cells. Exp. Eye Res. 1986; 43: 355–363
   PubMed Web of Science ®Google Scholar
• Jaffe G. J., Burke J. M., Geroski D. H. Ouabain-sensitive Na+-K+ ATPase pumps in cultured human retinal pigment epithelium. Exp. Eye Res. 1989; 48: 61–68
   PubMed Web of Science ®Google Scholar
• Bresnick E. Drug metabolism: Speculations on the future. Drug Me tab. Rev. 1979; 10: 311–313
   PubMed Web of Science ®Google Scholar
• Hardebo J. E., Emson P. C., Falck B., Owman C., Rosen-gren E. Enzymes related to monoamine transmitter metabolism in brain microvessels. J. Neurochem. 1980; 35: 1388–1393
   PubMed Web of Science ®Google Scholar
• Haenick D. H., Ladman R. K., Weiss J., Boehme D. H., Vogel W. H. Monoamine oxidase activities in human brain microvessels. Experientia 1981; 37: 764–765
   PubMedGoogle Scholar
• Lasbennes F., Sercombe R., Seylaz J. Monoamine oxidase activity in brain microvessels determined using natural and artificial substrates: Relevance to the blood-brain barrier. J. Cerebral Blood Flow and Metabolism 1983; 3: 521–528
   PubMed Web of Science ®Google Scholar
• Scriba G. K. E., Borchardt R. T. Metabolism of catecholamine esters by cultured bovine brain microvessel endothelial cells. J. Neu-rochem. 1989; 53: 610–615
   PubMed Web of Science ®Google Scholar
• Lorenzo A. V., Hammerstad J. P., Cutler R. W. P. The effect of anaesthetic agents on the cerebrospinal fluid clearance of 35S-sulphate and l25I-iodide. Biochem. Pharmacol. 1968; 17: 1279–1283
   PubMed Web of Science ®Google Scholar
• Wolfson L. I., Katzman R., Escriva A. Clearance of amine metabolites from the cerebrospinal fluid: The brain as a “sink,”. Neurology 1974; 24: 772–779
   PubMed Web of Science ®Google Scholar
• Davson H. Physiology of the Cerebrospinal Fluid. Little, Brown, Boston 1967
   Google Scholar
• Neff N. H., Tozer T. N., Brodie B. B. Application of steady-state kinetics to studies of the transfer of 5-hydroxyindoleacetic acid from brain to plasma. J. Pharmacol. Exp. Then 1967; 158: 214–218
   PubMed Web of Science ®Google Scholar
• Anderson J. A., Davis W. L., Wei C. -P. Site of ocular hydrolysis of a prodrug, dipivefrin, and a comparison of its ocular metabolism with that of the parent compound, epinephrine. Invest. Ophthalmol. Vis. Sci. 1980; 19: 817–823
   PubMed Web of Science ®Google Scholar
• Redell M. A., Yang D. C., Lee V. H. L. The role of esterase activity in the ocular disposition of dipivalyl epinephrine in rabbits. Int. J. Pharmaceut. 1983; 17: 299–312
   Web of Science ®Google Scholar
• Schoenwald R. D., Chien D. S. Ocular absorption and disposition of phenylephrine and phenylephrine oxazolidine. Biopharm. Drug Dispos. 1988; 9: 527–538
   PubMed Web of Science ®Google Scholar
• Schoenwald R. D., Huang H. -S. Corneal penetration behavior of B-blocking agents. I. Physicochemical factors. J. Pharm. Sci. 1983; 72: 1266–1271
   PubMed Web of Science ®Google Scholar
• Chang S. -C., Chien D. -S., Bundgaard H., Lee V. H. L. Relative effectiveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol. Exp. Eye Res. 1988; 46: 59–69
   PubMed Web of Science ®Google Scholar
• Chang S. -C., Bundgaard H., Buur A., Lee V. H. L. Low dose O-butyryl timolol improves the therapeutic index of timolol in the pigmented rabbit. Invest. Ophthalmol. Vis. Sci. 1988; 29: 626–629
   PubMed Web of Science ®Google Scholar
• Potter D. E., Shumate D. J., Bundgaard H., Lee V. H. L. Ocular and cardiac B-antagonism by timolol prodrugs, timolol and levobunolol. Curr. Eye Res. 1988; 7: 755–759
   PubMed Web of Science ®Google Scholar
• Buur A., Bundgaard H., Lee V. H. L. Prodrugs of propranolol: Hydrolysis and intramolecular aminolysis of various propranolol esters and an oxazolidin-2-one derivative. Int. J. Pharmaceut. 1988; 42: 51–60
   Web of Science ®Google Scholar
• Suzuki F., Hayashi H., Ito S., Hayaishi O. Methyl ester of prostaglandin D2 as a delivery system into brain. Biochim. Biophys. Acta 1987; 917: 224–230
   PubMed Web of Science ®Google Scholar
• Bito L. Z., Baroody R. A. The ocular pharmacokinetics of ei-cosanoids and their derivatives. 1. Comparisons of ocular eicosanoid penetration and distribution following the topical application of PGF2oi, PGF2a-l-methyl ester, and PGF2u-l-isopropyl ester. Exp. Eye Res. 1987; 44: 217–226
   PubMed Web of Science ®Google Scholar
• Bundgaard H., Falch E., Larsen C., Mosher G. L., Mikkel-son T. J. Pilocarpic acid esters as novel sequentially labile pilocarpine prodrugs for improved ocular delivery. J. Med. Chem. 1985; 28: 979–981
   PubMed Web of Science ®Google Scholar
• Mitra A. K., Mikkelson Y. J. Mechanism of transcorneal permeation of pilocarpine. J. Pharm. Sci. 1988; 77: 771–775
   PubMed Web of Science ®Google Scholar
• Chiou G. C. Y., Chuang C. Y., Chang M. S. Systemic delivery of enkephalin peptide through eyes. Life Sci. 1988; 43: 509–514
   PubMed Web of Science ®Google Scholar
• Narurkar M. M., Mitra A. K. Prodrugs of 5-iodo-2′ deoxyuri-dine for enhanced ocular transport. Pharmaceut. Res. 1989; 6: 887–891
   PubMed Web of Science ®Google Scholar
• Tsuji A., Tamai I., Sasaki K. Hydrolysis of prednisolone succinate by esterase in rabbit ocular tissues. Ophthalmic Res. 1987; 19: 322–329
   PubMed Web of Science ®Google Scholar
• Pardridge W. M. Strategies for drug delivery through the blood-brain barrier. Directed Drug Delivery, R. T. Borchardt, A. J. Repta, V. J. Stella. Humana Press, Clifton, NJ 1985; 83–96
   Google Scholar
• Bodor N. Redox drug delivery systems for targeting drugs to the brain. Ann. NY Acad. Sci. 1987; 507: 289–306
   PubMed Web of Science ®Google Scholar
• Bodor Koussi N., El A. Novel “soft” B-blockers as potential safe antiglaucoma agents. Curr. Eye Res. 1988; 7: 369–374
   PubMed Web of Science ®Google Scholar
• Audus K. L., Bartel R. L., Hidalgo I. J., Borchardt R. T. The use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharmaceut. Res. 1990; 7: 435–451
   PubMed Web of Science ®Google Scholar
• Rapoport S. I., Fredericks W. R., Ohno K., Pettigrew K. D. Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am. J. Physiol. 1980; 238: R421–R431
   PubMed Web of Science ®Google Scholar
• Li V., Turski P. A., Levin A. B., Weinstein J., Rozentai J., Strother C. M. Osmotic disruption of the blood-ocular barriers. Am. J. Neuroradiol. 1987; 8: 347–348
   PubMed Web of Science ®Google Scholar
• Pickard J. D., Durity F., Welch F. A., Langfitt T. -W., Harper A. M., MacKenzie E. T. Osmotic opening of the blood-brain barrier: Value in pharmacological studies on the cerebral circulation. Brain Res. 1977; 122: 170–176
   PubMed Web of Science ®Google Scholar
• Brightman M. W. Morphology of blood-brain interfaces. Exp. Eye Res. 1977; 1–25, Suppl.
   PubMed Web of Science ®Google Scholar
• Heistad D. D. Protection of the blood-brain barrier during acute and chronic hypertension. Fed. Proc 1984; 43: 205–209
   PubMedGoogle Scholar
• Hirano A., Ghatak N. R., Becker N. H., Zimmerman H. M. A comparison of the fine structure of small blood vessels in intracranial and retroperitoneal malignant lymphomas. Acta Neuropathol. 1971; 27: 93–104, as cited by Bradbury [555]
   Google Scholar
• Spector R., Lorenzo A. V. Inhibition of penicillin transport from the cerebrospinal fluid after intracisternal inoculation of bacteria. J. Clin. Invest. 1974; 54: 316–325
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J., Faria de Abreu J. R., Campos A. J., Figo G. M. Early breakdown of the blood-brain barrier in diabetes. Brit. J. Ophthalmol. 1975; 59: 649–656
   PubMed Web of Science ®Google Scholar
• Deutman A. F. Significance of alteration of the outer blood-retinal barrier. The Blood-Retinal Barriers, J. G. Cunha-Vaz. Plenum Press, New York 1979; 365–374
   Google Scholar
• Goldberg M. F. Diseases affecting the inner blood-retinal barrier. The Blood-Retinal Barriers, J. G. Cunha-Vaz. Plenum Press, New York 1979; 309–310
   Google Scholar
• Mallick K. S., Zeimer R. C., Fishman G. A., Blair N. P., Anderson R. J. Transport of fluorescein in the ocular posterior segment in retinitis pigmentosa. Arch. Opthalmol. 1984; 102: 691–696
   PubMed Web of Science ®Google Scholar
• Neuwelt E. A., Rapoport S. I. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed. Proc 1984; 43: 214–219
   PubMedGoogle Scholar
• McGahan M. C. Ascorbic acid levels in aqueous and vitreous humors of the rabbit: Effects of inflammation and ceruloplasmin. Exp. Eye Res. 1985; 41: 291–298
   PubMed Web of Science ®Google Scholar
• Ficker L., Meredith T. A., Gardner S., Wilson A. L. Cefazolin levels of after intravitreal injection. Effects of inflammation and surgery. Invest. Ophthalmol. Vis. Sci. 1990; 31: 502–505
   PubMed Web of Science ®Google Scholar
• Sanders D. R., Kraff M. C., Lieberman H. L., Peyman G. A., Tarabishy S. Breakdown and reestablishment of blood-aqueous barrier with implant surgery. Arch. Ophthalmol. 1982; 100: 588–590
   PubMed Web of Science ®Google Scholar
• Sloane J. P., Lwin K. Y., Gore M. E., Powles R. L., Smith J. F. Disturbance of blood-brain after bone-marrow transplantation. Lancet 1985; 2: 280–281
   PubMed Web of Science ®Google Scholar
• Eakins K. E. Prostaglandin-and non-prostaglandin-mediated breakdown of the blood-aqueous barrier. Exp. Eye Res. 1977; 25: 483–498, Suppl.
   PubMed Web of Science ®Google Scholar
• Tsuboi S., Tsuboi J. E. Pederson, Acetazolamide effect on the inward permeability of the blood-retinal barrier to carboxyfluorescein. Invest. Ophthalmol. Vis. Sci. 1987; 28: 92–95
   PubMed Web of Science ®Google Scholar
• Saija A., Princi P., De Pasquale R., Costa G. Arecoline, but not haloperidol, induces changes in the permeability of the blood-brain barrier in the rat. J. Pharm. Pharmacol 1989; 42: 135–138
   Web of Science ®Google Scholar
• Novack G. D., Leopold I. H. The blood-aqueous and blood-brain barriers to permeability. Am. J. Ophthalmol. 1988; 105: 412–416
   PubMed Web of Science ®Google Scholar
• Pardridge W. M., Connor J. D., Crawford I. L. Permeability changes in blood-brain barrier: Causes and consequences. CRC Crit. Rev. Toxicol. 1975; 3: 159–199
   PubMedGoogle Scholar
• Plazonnet B., Grove J., Durr M., Mazuel C., Quint M., Ro-zier A. Pharmacokinetics and biopharmaceutical aspects of some anti-glaucoma drugs. Ophthalmic Drug Delivery: Biopharmaceutical, Technological and Clinical Aspects. Liviana Press/Springer-Verlag, Berlin 1987; vol. 11: 118–139
   Google Scholar
• Nabeshima T., Fontenot J., Ho I. K. Effects of chronic administration of pentobarbital or morphine on the brain microsomal cytochrome P-450 system. Biochem. Pharmacol. 1981; 30: 1142–1145
   PubMed Web of Science ®Google Scholar
• Rang Y. S., Terasaki T., Ohnishi T., Tsuji A. In vivo and in vitro evidence for a common carrier mediated transport of choline and basic drugs through the blood–brain barrier. J. Pharmacohio-Dyn. 1990; 13: 353–360
   PubMedGoogle Scholar